Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome

Mendelian MONDO:0009393 Pathograph 57 Urea cycle disorder Inborn error of metabolism

Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome is an autosomal recessive urea-cycle transport disorder caused by biallelic SLC25A15 loss of function. Defective mitochondrial ornithine transport produces hyperornithinemia, hyperammonemia, urinary homocitrulline, and often oroticaciduria, with episodic hyperammonemic encephalopathy, progressive neurocognitive and pyramidal tract involvement, and liver dysfunction.

Ask OpenScientist

Ask a research question about Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
7
Pathophys.
40
Phenotypes
57
Pathograph
1
Genes
4
Treatments
7
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0009393 ornithine translocase deficiency
skos:exactMatch MONDO
MONDO exact match for Orphanet ORPHA:415 and OMIM:238970.
👪

Inheritance

1
Autosomal recessive HP:0000007
Autosomal recessive inheritance
Show evidence (2 references)
ORPHA:415 SUPPORT Other
"Autosomal recessive"
Orphanet records autosomal recessive inheritance.
PMID:36506307 SUPPORT Human Clinical
"Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) syndrome, is a rare autosomal recessive disorder characterized by impaired ornithine transport across the inner mitochondrial membrane."
Human cohort report directly states the autosomal recessive inheritance pattern.
⚙

Pathophysiology

7
SLC25A15 Loss of Function
Biallelic SLC25A15 pathogenic variants reduce ORC1/ORNT1 mitochondrial ornithine carrier function, the initiating molecular lesion in HHH syndrome.
SLC25A15 link
amino acid transmembrane transporter activity link ↓ DECREASED
mitochondrial inner membrane link
Downstream
Mitochondrial Ornithine Transport Defect Loss of ORC1/ORNT1 function directly impairs mitochondrial ornithine transport.
Show evidence (2 references)
ORPHA:415 SUPPORT Other
"SLC25A15 | solute carrier family 25 member 15 | hgnc:10985 | Disease-causing germline mutation(s) (loss of function) in"
Orphanet identifies SLC25A15 loss-of-function germline variants as disease causing.
PMID:39086438 SUPPORT Human Clinical
"Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome, an inborn error of metabolism, is an inherited syndrome caused by loss-of-function mutations in the SLC25A15, resulting in ornithine translocase1 (ORNT1) deficiency."
Patient report directly supports SLC25A15 loss of function as the causal molecular defect.
Mitochondrial Ornithine Transport Defect
Defective ORC1 transport prevents normal movement of ornithine into mitochondria, disrupting the mitochondrial entry point needed for ornithine-dependent urea-cycle flux.
ornithine transport link ↓ DECREASED
mitochondrial inner membrane link
Downstream
Hyperornithinemia Impaired mitochondrial ornithine entry causes systemic ornithine accumulation.
Chorioretinal atrophy Rare ocular involvement is reported in the HHH phenotype spectrum and is linked here to the chronic hyperornithinemic transport-defect state.
Chorioretinal hypopigmentation Rare chorioretinal hypopigmentation is represented as ocular involvement downstream of the chronic ornithine transport defect.
Urea Cycle Flux Impairment Mitochondrial ornithine deficiency reduces ornithine-dependent urea-cycle flux.
Show evidence (2 references)
PMID:25874378 SUPPORT Human Clinical
"HHH syndrome is caused by impaired ornithine transport across the inner mitochondrial membrane due to mutations in SLC25A15 gene, which encodes for the mitochondrial ornithine carrier ORC1."
Directly supports the mitochondrial ornithine transport defect.
PMID:36506307 SUPPORT Human Clinical
"HHH is caused by biallelic disease-causing variants in the SLC25A15 gene."
Cohort evidence supports biallelic SLC25A15 variants as the driver of the transport defect.
Urea Cycle Flux Impairment
Reduced mitochondrial ornithine availability functionally impairs the urea cycle, lowering hepatic nitrogen disposal and producing hyperammonemia.
urea cycle link ↓ DECREASED
liver link
Downstream
Hyperammonemia Impaired urea-cycle nitrogen disposal produces elevated ammonia.
Hyperammonemic Encephalopathy Elevated ammonia during impaired urea-cycle flux drives acute encephalopathic decompensation.
Carbamoyl Phosphate Diversion Reduced ornithine availability leaves carbamoyl phosphate available for diversion into orotic acid and homocitrulline pathways.
Liver Dysfunction and Coagulation Abnormality The urea-cycle transport defect is associated with acute and chronic hepatic dysfunction, transaminase elevation, and coagulation abnormalities.
Respiratory alkalosis Hyperammonemic urea-cycle decompensation can present with tachypnea and respiratory alkalosis.
Protein avoidance Chronic nitrogen intolerance can manifest as aversion to protein-rich foods.
Failure to thrive Recurrent metabolic stress and chronic protein intolerance contribute to poor growth.
Abnormality of citrulline metabolism Disturbed mitochondrial ornithine entry perturbs urea-cycle intermediate handling, including circulating citrulline.
Show evidence (2 references)
PMID:25874378 SUPPORT Human Clinical
"BACKGROUND: Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome is a rare autosomal recessive disorder of the urea cycle."
The HHH review frames the disorder as a urea-cycle disorder.
PMID:30853934 SUPPORT Human Clinical
"Interestingly, two urea cycle disorders, Argininemia and Hyperornithinemia-Hyperammonemia-Homocitrullinuria syndrome, are clinically characterized by highly penetrant spastic paraplegia."
Review evidence independently identifies HHH syndrome as a urea-cycle disorder.
Carbamoyl Phosphate Diversion
When ornithine-dependent mitochondrial flux is impaired, excess carbamoyl phosphate is reflected clinically by urinary homocitrulline and often orotic acid abnormalities.
Downstream
Homocitrullinuria Carbamoyl-phosphate diversion produces urinary homocitrulline.
Oroticaciduria Orotic acid abnormalities can occur as part of the diverted carbamoyl-phosphate state.
Show evidence (2 references)
PMID:25874378 SUPPORT Human Clinical
"The diagnosis relies on clinical signs and the peculiar metabolic triad of hyperammonemia, hyperornithinemia, and urinary excretion of homocitrulline."
The systematic review identifies urinary homocitrulline as part of the diagnostic triad.
PMID:39597062 SUPPORT Human Clinical
"Three out of four cases presented with hyperammonemia, elevated transaminases, and uraciluria."
Vietnamese cohort documents pyrimidine-pathway urinary abnormalities in HHH patients.
Hyperammonemic Encephalopathy
Hyperammonemic crises produce acute encephalopathy with vomiting, confusion, lethargy, and coma; recurrent or severe episodes contribute to long-term neurologic injury.
Downstream
Acute encephalopathy Hyperammonemia manifests clinically as acute encephalopathy.
Lethargy Acute hyperammonemic encephalopathy can present with lethargy.
Confusion Hyperammonemic encephalopathy can manifest as episodic confusion.
Coma Severe acute hyperammonemic encephalopathy can progress to coma.
Episodic vomiting Acute metabolic decompensation includes intermittent vomiting.
Feeding difficulties Neonatal or infantile hyperammonemic decompensation can present with poor feeding.
Tachypnea Acute metabolic decompensation can include tachypnea.
Seizure Hyperammonemic brain dysfunction can include seizures during the HHH disease course.
Generalized myoclonic seizure Myoclonic seizures occur within the chronic and episodic neurologic HHH phenotype.
Chronic Neurocognitive and Pyramidal Tract Dysfunction Recurrent metabolic injury and disease-specific mechanisms are associated with chronic neurocognitive and pyramidal tract involvement.
Show evidence (2 references)
PMID:25874378 SUPPORT Human Clinical
"Acute clinical signs include intermittent episodes of vomiting, confusion or coma and hepatitis-like attacks."
Systematic review directly describes acute encephalopathic signs in HHH syndrome.
PMID:36506307 SUPPORT Human Clinical
"The major acute clinical presentation found was encephalopathy and liver dysfunction."
Cohort evidence identifies encephalopathy as a major acute presentation.
Chronic Neurocognitive and Pyramidal Tract Dysfunction
Chronic HHH syndrome commonly involves neurodevelopmental delay, cognitive impairment, learning disability, ataxia, spastic paraplegia, hyperreflexia, clonus, and other pyramidal signs.
Downstream
Spastic paraplegia Pyramidal tract involvement can manifest as spastic paraplegia.
Abnormal pyramidal sign Progressive upper-motor-neuron involvement produces abnormal pyramidal signs.
Hyperreflexia Upper-motor-neuron involvement commonly manifests as hyperreflexia.
Clonus Pyramidal tract dysfunction can manifest as clonus.
Spastic gait Pyramidal tract dysfunction can produce a spastic gait pattern.
Cognitive impairment Progressive neurologic involvement includes variable cognitive impairment.
Intellectual disability Chronic neurocognitive involvement includes developmental delay and intellectual disability.
Neurodevelopmental delay Chronic neurologic involvement often includes neurodevelopmental delay.
Specific learning disability Chronic cognitive involvement can manifest as learning disability.
Progressive cerebellar ataxia Chronic neurologic involvement includes progressive ataxia.
Poor coordination Cerebellar and motor-system involvement can manifest as poor coordination.
Generalized hypotonia Early neurologic involvement can include generalized hypotonia.
Impaired vibratory sensation Chronic neurologic involvement can include sensory pathway impairment.
Speech apraxia Chronic neurodevelopmental and motor-planning involvement can manifest as speech apraxia.
Cerebral cortical atrophy Chronic neurologic injury is associated with cerebral cortical atrophy in the HHH phenotype spectrum.
Multifocal cerebral white matter abnormalities Chronic neurologic disease can include multifocal cerebral white matter abnormalities.
Show evidence (2 references)
PMID:25874378 SUPPORT Human Clinical
"Alternatively, patients show a chronic course with aversion for protein rich foods, developmental delay/intellectual disability, myoclonic seizures, ataxia and pyramidal dysfunction."
Systematic review directly supports the chronic neurologic phenotype cluster.
PMID:36506307 SUPPORT Human Clinical
"Nervous system involvement was common, progressive, and presented with signs of upper motor neuron disease as well as variable degrees of cognitive impairment."
Cohort evidence supports progressive upper-motor-neuron and cognitive involvement.
Liver Dysfunction and Coagulation Abnormality
HHH syndrome frequently includes decreased liver function, transaminase elevation, hepatitis-like attacks, and coagulation abnormalities; severe cases can present with hepatic failure.
liver link
Downstream
Decreased liver function Hepatic involvement manifests as decreased liver function.
Hepatitis HHH hepatic involvement can include hepatitis-like attacks.
Hepatic failure Severe hepatic involvement can progress to hepatic failure in rare cases.
Hepatomegaly Hepatic involvement can manifest as hepatomegaly.
Elevated circulating hepatic transaminase concentration Liver injury in HHH syndrome is reflected by elevated circulating hepatic transaminases.
Elevated hepatic transaminases Elevated hepatic transaminases provide a biochemical readout of the liver-dysfunction branch.
Abnormality of the coagulation cascade Hepatic dysfunction can be accompanied by coagulation abnormalities.
Show evidence (2 references)
ORPHA:415 SUPPORT Other
"HP:0001410 | Decreased liver function | Frequent (79-30%)"
Orphanet records decreased liver function as frequent.
PMID:36506307 SUPPORT Human Clinical
"The major acute clinical presentation found was encephalopathy and liver dysfunction."
Cohort evidence supports liver dysfunction as a major acute manifestation.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

40
Blood 1
Abnormality of the coagulation cascade OCCASIONAL Abnormality of the coagulation cascade (HP:0003256)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0003256 | Abnormality of the coagulation cascade | Occasional (29-5%)"
Orphanet lists coagulation-cascade abnormality as an occasional phenotype.
Digestive 5
Hepatic failure VERY_RARE Hepatic failure (HP:0001399)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0001399 | Hepatic failure | Very rare (<4-1%)"
Orphanet lists hepatic failure as a very rare phenotype.
Decreased liver function FREQUENT Decreased liver function (HP:0001410)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0001410 | Decreased liver function | Frequent (79-30%)"
Orphanet lists decreased liver function as a frequent phenotype.
Hepatomegaly FREQUENT Hepatomegaly (HP:0002240)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0002240 | Hepatomegaly | Frequent (79-30%)"
Orphanet lists hepatomegaly as a frequent phenotype.
Feeding difficulties FREQUENT Feeding difficulties (HP:0011968)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0011968 | Feeding difficulties | Frequent (79-30%)"
Orphanet lists feeding difficulties as a frequent phenotype.
Hepatitis FREQUENT Hepatitis (HP:0012115)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0012115 | Hepatitis | Frequent (79-30%)"
Orphanet lists hepatitis as a frequent phenotype.
Genitourinary 1
Oroticaciduria FREQUENT Oroticaciduria (HP:0003218)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0003218 | Oroticaciduria | Frequent (79-30%)"
Orphanet lists oroticaciduria as a frequent phenotype.
Metabolism 3
Respiratory alkalosis OCCASIONAL Respiratory alkalosis (HP:0001950)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0001950 | Respiratory alkalosis | Occasional (29-5%)"
Orphanet lists respiratory alkalosis as an occasional phenotype.
Hyperammonemia VERY_FREQUENT Hyperammonemia (HP:0001987)
Show evidence (2 references)
ORPHA:415 SUPPORT Other
"HP:0001987 | Hyperammonemia | Very frequent (99-80%)"
Orphanet lists hyperammonemia as a very frequent phenotype.
PMID:39597062 SUPPORT Human Clinical
"Three out of four cases presented with hyperammonemia, elevated transaminases, and uraciluria."
Human cohort data support hyperammonemia as a common biochemical-clinical feature.
Elevated circulating hepatic transaminase concentration FREQUENT Elevated circulating hepatic transaminase concentration (HP:0002910)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0002910 | Elevated circulating hepatic transaminase concentration | Frequent (79-30%)"
Orphanet lists elevated circulating hepatic transaminase concentration as a frequent phenotype.
Musculoskeletal 2
Spastic paraplegia FREQUENT Spastic paraplegia (HP:0001258)
Show evidence (2 references)
ORPHA:415 SUPPORT Other
"HP:0001258 | Spastic paraplegia | Frequent (79-30%)"
Orphanet lists spastic paraplegia as a frequent phenotype.
PMID:30853934 SUPPORT Human Clinical
"Hyperornithinemia-Hyperammonemia-Homocitrullinuria syndrome, are clinically characterized by highly penetrant spastic paraplegia."
Literature review supports spastic paraplegia as a prominent clinical phenotype.
Generalized hypotonia FREQUENT Generalized hypotonia (HP:0001290)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0001290 | Generalized hypotonia | Frequent (79-30%)"
Orphanet lists generalized hypotonia as a frequent phenotype.
Nervous System 13
Intellectual disability FREQUENT Intellectual disability (HP:0001249)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0001249 | Intellectual disability | Frequent (79-30%)"
Orphanet lists intellectual disability as a frequent phenotype.
Seizure OCCASIONAL Seizure (HP:0001250)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0001250 | Seizure | Occasional (29-5%)"
Orphanet lists seizure as an occasional phenotype.
Lethargy FREQUENT Lethargy (HP:0001254)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0001254 | Lethargy | Frequent (79-30%)"
Orphanet lists lethargy as a frequent phenotype.
Coma OCCASIONAL Coma (HP:0001259)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0001259 | Coma | Occasional (29-5%)"
Orphanet lists coma as an occasional phenotype.
Confusion FREQUENT Confusion (HP:0001289)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0001289 | Confusion | Frequent (79-30%)"
Orphanet lists confusion as a frequent phenotype.
Hyperreflexia VERY_FREQUENT Hyperreflexia (HP:0001347)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0001347 | Hyperreflexia | Very frequent (99-80%)"
Orphanet lists hyperreflexia as a very frequent phenotype.
Progressive cerebellar ataxia FREQUENT Progressive cerebellar ataxia (HP:0002073)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0002073 | Progressive cerebellar ataxia | Frequent (79-30%)"
Orphanet lists progressive cerebellar ataxia as a frequent phenotype.
Cerebral cortical atrophy FREQUENT Cerebral cortical atrophy (HP:0002120)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0002120 | Cerebral cortical atrophy | Frequent (79-30%)"
Orphanet lists cerebral cortical atrophy as a frequent phenotype.
Generalized myoclonic seizure OCCASIONAL Generalized myoclonic seizure (HP:0002123)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0002123 | Generalized myoclonic seizure | Occasional (29-5%)"
Orphanet lists generalized myoclonic seizure as an occasional phenotype.
Acute encephalopathy FREQUENT Acute encephalopathy (HP:0006846)
Show evidence (2 references)
ORPHA:415 SUPPORT Other
"HP:0006846 | Acute encephalopathy | Frequent (79-30%)"
Orphanet lists acute encephalopathy as a frequent phenotype.
PMID:36506307 SUPPORT Human Clinical
"The major acute clinical presentation found was encephalopathy and liver dysfunction."
Cohort evidence supports acute encephalopathy as a major presentation.
Speech apraxia FREQUENT Speech apraxia (HP:0011098)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0011098 | Speech apraxia | Frequent (79-30%)"
Orphanet lists speech apraxia as a frequent phenotype.
Neurodevelopmental delay VERY_FREQUENT Neurodevelopmental delay (HP:0012758)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0012758 | Neurodevelopmental delay | Very frequent (99-80%)"
Orphanet lists neurodevelopmental delay as a very frequent phenotype.
Cognitive impairment VERY_FREQUENT Cognitive impairment (HP:0100543)
Show evidence (2 references)
ORPHA:415 SUPPORT Other
"HP:0100543 | Cognitive impairment | Very frequent (99-80%)"
Orphanet lists cognitive impairment as a very frequent phenotype.
PMID:36506307 SUPPORT Human Clinical
"Nervous system involvement was common, progressive, and presented with signs of upper motor neuron disease as well as variable degrees of cognitive impairment."
Cohort evidence directly supports cognitive impairment.
Respiratory 1
Tachypnea FREQUENT Tachypnea (HP:0002789)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0002789 | Tachypnea | Frequent (79-30%)"
Orphanet lists tachypnea as a frequent phenotype.
Growth 1
Failure to thrive FREQUENT Failure to thrive (HP:0001508)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0001508 | Failure to thrive | Frequent (79-30%)"
Orphanet lists failure to thrive as a frequent phenotype.
Other 13
Chorioretinal atrophy VERY_RARE Chorioretinal atrophy (HP:0000533)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0000533 | Chorioretinal atrophy | Very rare (<4-1%)"
Orphanet lists chorioretinal atrophy as a very rare HHH syndrome phenotype.
Specific learning disability FREQUENT Specific learning disability (HP:0001328)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0001328 | Specific learning disability | Frequent (79-30%)"
Orphanet lists specific learning disability as a frequent phenotype.
Protein avoidance FREQUENT Protein avoidance (HP:0002038)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0002038 | Protein avoidance | Frequent (79-30%)"
Orphanet lists protein avoidance as a frequent phenotype.
Spastic gait OCCASIONAL Spastic gait (HP:0002064)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0002064 | Spastic gait | Occasional (29-5%)"
Orphanet lists spastic gait as an occasional phenotype.
Clonus FREQUENT Clonus (HP:0002169)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0002169 | Clonus | Frequent (79-30%)"
Orphanet lists clonus as a frequent phenotype.
Poor coordination FREQUENT Incoordination (HP:0002311)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0002370 | Poor coordination | Frequent (79-30%)"
Orphanet lists poor coordination as a frequent phenotype; the obsolete HPO row is represented with the current Incoordination term whose synonyms include poor coordination.
Impaired vibratory sensation FREQUENT Impaired vibratory sensation (HP:0002495)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0002495 | Impaired vibratory sensation | Frequent (79-30%)"
Orphanet lists impaired vibratory sensation as a frequent phenotype.
Episodic vomiting FREQUENT Episodic vomiting (HP:0002572)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0002572 | Episodic vomiting | Frequent (79-30%)"
Orphanet lists episodic vomiting as a frequent phenotype.
Multifocal cerebral white matter abnormalities OCCASIONAL Multifocal cerebral white matter abnormalities (HP:0007052)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0007052 | Multifocal cerebral white matter abnormalities | Occasional (29-5%)"
Orphanet lists multifocal cerebral white matter abnormalities as an occasional phenotype.
Abnormal pyramidal sign FREQUENT Abnormal pyramidal sign (HP:0007256)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0007256 | Abnormal pyramidal sign | Frequent (79-30%)"
Orphanet lists abnormal pyramidal sign as a frequent phenotype.
Abnormality of citrulline metabolism VERY_FREQUENT Abnormal circulating citrulline concentration (HP:0011965)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0011965 | Abnormality of citrulline metabolism | Very frequent (99-80%)"
Orphanet lists abnormality of citrulline metabolism as a very frequent phenotype.
Hyperornithinemia VERY_FREQUENT Hyperornithinemia (HP:0012026)
Show evidence (2 references)
ORPHA:415 SUPPORT Other
"HP:0012026 | Hyperornithinemia | Very frequent (99-80%)"
Orphanet lists hyperornithinemia as a very frequent phenotype.
PMID:39597062 SUPPORT Human Clinical
"All four cases demonstrated hyperornithinemia and prolonged prothrombin time."
Vietnamese cohort data support hyperornithinemia as a consistent biochemical feature in that cohort.
Chorioretinal hypopigmentation VERY_RARE Chorioretinal hypopigmentation (HP:0040030)
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0040030 | Chorioretinal hypopigmentation | Very rare (<4-1%)"
Orphanet lists chorioretinal hypopigmentation as a very rare phenotype.
🧬

Genetic Associations

1
SLC25A15 pathogenic variants
Autosomal recessive
Show evidence (2 references)
ORPHA:415 SUPPORT Other
"SLC25A15 | solute carrier family 25 member 15 | hgnc:10985 | Disease-causing germline mutation(s) (loss of function) in"
Orphanet identifies SLC25A15 loss-of-function germline variants as causal.
PMID:36506307 SUPPORT Human Clinical
"There was no clear genotype-phenotype correlation."
Cohort data support incomplete genotype-phenotype correlation.
💊

Treatments

4
Protein-restricted diet
Action: dietary intervention MAXO:0000088
Chronic dietary protein restriction lowers nitrogen load and is a core long-term strategy for controlling hyperammonemia.
Mechanism Target:
MODULATES Urea Cycle Flux Impairment — Dietary nitrogen reduction decreases the burden on impaired urea-cycle flux.
Show evidence (1 reference)
PMID:25874378 SUPPORT Human Clinical
"Acute and chronic management consists in the control of hyperammonemia with protein-restricted diet supplemented with citrulline/arginine and ammonia scavengers."
Review evidence directly supports protein restriction as part of acute and chronic management.
Target Phenotypes: Hyperammonemia ↗
Show evidence (1 reference)
PMID:25874378 SUPPORT Human Clinical
"Acute and chronic management consists in the control of hyperammonemia with protein-restricted diet supplemented with citrulline/arginine and ammonia scavengers."
Systematic review identifies protein-restricted diet as part of HHH syndrome management.
Citrulline and arginine supplementation
Action: nutritional supplementation MAXO:0000106
Agent: citrulline ↗ L-arginine ↗
Citrulline or arginine supplementation is used with dietary management to support urea-cycle intermediate availability and biochemical control.
Mechanism Target:
MODULATES Urea Cycle Flux Impairment — Citrulline or arginine supplementation supports residual urea-cycle flux.
Show evidence (1 reference)
PMID:25874378 SUPPORT Human Clinical
"Acute and chronic management consists in the control of hyperammonemia with protein-restricted diet supplemented with citrulline/arginine and ammonia scavengers."
Review evidence directly supports citrulline/arginine supplementation in HHH syndrome management.
Target Phenotypes: Hyperammonemia ↗
Show evidence (1 reference)
PMID:25874378 SUPPORT Human Clinical
"Acute and chronic management consists in the control of hyperammonemia with protein-restricted diet supplemented with citrulline/arginine and ammonia scavengers."
Systematic review identifies citrulline/arginine supplementation as part of management.
Ammonia scavenger therapy
Action: Pharmacotherapy NCIT:C15986
Agent: sodium benzoate ↗ sodium phenylbutyrate ↗
Ammonia scavengers are used to control ammonia in HHH syndrome, providing alternative nitrogen-disposal routes when urea-cycle flux is impaired.
Mechanism Target:
BYPASSES Urea Cycle Flux Impairment — Ammonia scavengers bypass impaired ureagenesis through alternative urinary nitrogen-disposal pathways.
Show evidence (1 reference)
PMID:33409766 SUPPORT Human Clinical
"Ammonia is diverted to the glycine and hippuric acid pathway by benzoate, and to the glutamine and phenylacetylglutamine pathway allowing elimination in the urine without passing through the urea cycle"
UCD management review supports the bypass mechanism for benzoate and phenylbutyrate-related scavenger therapy.
Target Phenotypes: Hyperammonemia ↗
Show evidence (2 references)
PMID:25874378 SUPPORT Human Clinical
"Acute and chronic management consists in the control of hyperammonemia with protein-restricted diet supplemented with citrulline/arginine and ammonia scavengers."
HHH syndrome review identifies ammonia scavengers as part of management.
PMID:33409766 SUPPORT Human Clinical
"Ammonia is diverted to the glycine and hippuric acid pathway by benzoate, and to the glutamine and phenylacetylglutamine pathway allowing elimination in the urine without passing through the urea cycle"
UCD management review names benzoate and the phenylacetylglutamine pathway underlying phenylbutyrate therapy.
Acute hyperammonemic crisis management
Action: supportive care MAXO:0000950
Acute metabolic decompensation requires urgent correction of ammonia and metabolite imbalances to reduce risk of irreversible neurologic injury.
Mechanism Target:
INHIBITS Hyperammonemic Encephalopathy — Rapid ammonia and metabolite correction reduces the encephalopathy cascade.
Show evidence (1 reference)
PMID:39086438 SUPPORT Human Clinical
"Correction of the accumulating metabolites is necessary to prevent irreversible neurological impairment."
Case report directly supports urgent correction of accumulating metabolites to prevent neurologic injury.
Target Phenotypes: Hyperammonemia ↗ Acute encephalopathy ↗
Show evidence (1 reference)
PMID:39086438 SUPPORT Human Clinical
"Correction of the accumulating metabolites is necessary to prevent irreversible neurological impairment."
HHH case report supports acute metabolic correction as necessary to prevent irreversible neurologic sequelae.
🔬

Biochemical Markers

5
Hyperornithinemia (INCREASED)
Context: Elevated plasma ornithine is a defining biochemical feature of HHH syndrome and reflects failure of mitochondrial ornithine uptake.
Pathograph Readouts
Readout Of Mitochondrial Ornithine Transport Defect Positive Diagnostic
Elevated ornithine reports failed mitochondrial ornithine uptake due to ORC1/ORNT1 transport deficiency.
Show evidence (1 reference)
PMID:39597062 SUPPORT Human Clinical
"Ornithine carrier 1 deficiency causes HHH syndrome, characterized by failure of mitochondrial ornithine uptake, hyperammonemia, and accumulation of ornithine and lysine in the cytoplasm."
Human cohort evidence directly connects failed mitochondrial ornithine uptake to ornithine accumulation.
Show evidence (1 reference)
PMID:39597062 SUPPORT Human Clinical
"All four cases demonstrated hyperornithinemia and prolonged prothrombin time."
Cohort data document hyperornithinemia.
Hyperammonemia (INCREASED)
Context: Elevated ammonia is a core biochemical abnormality and the driver of acute metabolic encephalopathy.
Pathograph Readouts
Readout Of Urea Cycle Flux Impairment Positive Diagnostic
Elevated ammonia reports impaired hepatic urea-cycle nitrogen disposal.
Show evidence (1 reference)
PMID:39597062 SUPPORT Human Clinical
"Three out of four cases presented with hyperammonemia, elevated transaminases, and uraciluria."
Human cohort data support hyperammonemia as a biochemical readout of the impaired urea-cycle branch.
Show evidence (1 reference)
PMID:39597062 SUPPORT Human Clinical
"Three out of four cases presented with hyperammonemia, elevated transaminases, and uraciluria."
Human cohort data support increased ammonia.
Homocitrullinuria (INCREASED)
Context: Urinary homocitrulline is part of the characteristic diagnostic triad, although some modern cohorts report incomplete expression.
Pathograph Readouts
Readout Of Carbamoyl Phosphate Diversion Positive Diagnostic
Urinary homocitrulline reports carbamoyl-phosphate diversion when ornithine-dependent urea-cycle flux is impaired.
Show evidence (1 reference)
PMID:25874378 SUPPORT Human Clinical
"The diagnosis relies on clinical signs and the peculiar metabolic triad of hyperammonemia, hyperornithinemia, and urinary excretion of homocitrulline."
The diagnostic triad supports urinary homocitrulline as a readout of the diverted urea-cycle intermediate state.
Show evidence (1 reference)
PMID:25874378 SUPPORT Human Clinical
"The diagnosis relies on clinical signs and the peculiar metabolic triad of hyperammonemia, hyperornithinemia, and urinary excretion of homocitrulline."
Systematic review identifies urinary homocitrulline as part of the diagnostic triad.
Oroticaciduria (INCREASED)
Context: Oroticaciduria or related urinary pyrimidine abnormalities can occur as a secondary biochemical marker of carbamoyl phosphate diversion.
Pathograph Readouts
Readout Of Carbamoyl Phosphate Diversion Positive Diagnostic
Oroticaciduria reports diversion of excess carbamoyl phosphate into pyrimidine-pathway products.
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0003218 | Oroticaciduria | Frequent (79-30%)"
Orphanet supports oroticaciduria as a frequent biochemical manifestation of the carbamoyl-phosphate diversion branch.
Show evidence (1 reference)
ORPHA:415 SUPPORT Other
"HP:0003218 | Oroticaciduria | Frequent (79-30%)"
Orphanet records oroticaciduria as frequent.
Elevated hepatic transaminases (INCREASED)
Context: Elevated hepatic transaminases accompany liver dysfunction during acute or chronic HHH syndrome presentations.
Pathograph Readouts
Readout Of Liver Dysfunction and Coagulation Abnormality Positive Monitoring
Elevated hepatic transaminases report the liver-dysfunction branch of HHH syndrome.
Show evidence (1 reference)
PMID:39597062 SUPPORT Human Clinical
"Three out of four cases presented with hyperammonemia, elevated transaminases, and uraciluria."
Human cohort data directly document elevated transaminases accompanying HHH presentations.
Show evidence (1 reference)
PMID:39597062 SUPPORT Human Clinical
"Three out of four cases presented with hyperammonemia, elevated transaminases, and uraciluria."
Cohort data document elevated transaminases.
{ }

Source YAML

click to show 
name: Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome
creation_date: "2026-05-11T07:39:50Z"
updated_date: "2026-05-21T04:16:09Z"
category: Mendelian
synonyms:
- HHH syndrome
- ORNT1 deficiency
- Ornithine carrier deficiency
- Ornithine translocase deficiency
- Triple H syndrome
description: >-
  Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome is an autosomal
  recessive urea-cycle transport disorder caused by biallelic SLC25A15 loss of
  function. Defective mitochondrial ornithine transport produces
  hyperornithinemia, hyperammonemia, urinary homocitrulline, and often
  oroticaciduria, with episodic hyperammonemic encephalopathy, progressive
  neurocognitive and pyramidal tract involvement, and liver dysfunction.
disease_term:
  preferred_term: hyperornithinemia-hyperammonemia-homocitrullinuria syndrome
  term:
    id: MONDO:0009393
    label: ornithine translocase deficiency
parents:
- Urea cycle disorder
- Inborn error of metabolism
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0009393
      label: ornithine translocase deficiency
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: MONDO exact match for Orphanet ORPHA:415 and OMIM:238970.
prevalence:
- population: Europe
  percentage: "<1 / 1 000 000"
  notes: Orphanet reports European point prevalence below 1 per 1,000,000.
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "<1 / 1 000 000 | Europe | Point prevalence | PMID:2013"
    explanation: Orphanet provides the European point-prevalence estimate for HHH syndrome.
- population: United States
  percentage: "<1 / 1 000 000"
  notes: Orphanet reports United States prevalence at birth below 1 per 1,000,000.
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "<1 / 1 000 000 | United States | Prevalence at birth | PMID:23972786"
    explanation: Orphanet provides a United States prevalence-at-birth estimate.
- population: Worldwide published cases
  notes: The central HHH systematic review evaluated 111 reported patients.
  evidence:
  - reference: PMID:25874378
    reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We retrospectively evaluated the clinical, biochemical and genetic profile of 111 HHH syndrome patients, 109 reported in 61 published articles, and two unpublished cases."
    explanation: A systematic review quantified the published HHH patient cohort.
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet records autosomal recessive inheritance.
  - reference: PMID:36506307
    reference_title: "Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) syndrome, is a rare autosomal recessive disorder characterized by impaired ornithine transport across the inner mitochondrial membrane."
    explanation: Human cohort report directly states the autosomal recessive inheritance pattern.
progression:
- phase: Variable neonatal to adult-onset urea-cycle transport disorder
  age_range: Neonatal period through adulthood
  notes: >-
    HHH syndrome may present neonatally with feeding difficulty, vomiting,
    lethargy, and tachypnea, but more commonly presents later with acute
    encephalopathic episodes, chronic neurocognitive involvement, progressive
    pyramidal tract signs, and liver dysfunction. Severity is variable and does
    not correlate reliably with genotype or recorded ammonium/ornithine levels.
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Neonatal"
    explanation: Orphanet records neonatal onset as part of the HHH syndrome spectrum.
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Adult"
    explanation: Orphanet records adult onset, supporting a broad age range.
  - reference: PMID:25874378
    reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Prognosis of HHH syndrome is variable, ranging from a severe course with disabling manifestations to milder variants compatible with an almost normal life."
    explanation: The systematic review summarizes the variable clinical course.
  - reference: PMID:36506307
    reference_title: "Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There was no clear genotype-phenotype correlation."
    explanation: The Palestinian cohort supports incomplete genotype-phenotype correlation.
pathophysiology:
- name: SLC25A15 Loss of Function
  description: >-
    Biallelic SLC25A15 pathogenic variants reduce ORC1/ORNT1 mitochondrial
    ornithine carrier function, the initiating molecular lesion in HHH syndrome.
  genes:
  - preferred_term: SLC25A15
    term:
      id: hgnc:10985
      label: SLC25A15
  molecular_functions:
  - preferred_term: amino acid transmembrane transporter activity
    term:
      id: GO:0015171
      label: amino acid transmembrane transporter activity
    modifier: DECREASED
  cellular_components:
  - preferred_term: mitochondrial inner membrane
    term:
      id: GO:0005743
      label: mitochondrial inner membrane
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SLC25A15 | solute carrier family 25 member 15 | hgnc:10985 | Disease-causing germline mutation(s) (loss of function) in"
    explanation: Orphanet identifies SLC25A15 loss-of-function germline variants as disease causing.
  - reference: PMID:39086438
    reference_title: "A Novel Mutation of ORNT1 Detected in a Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome Child by Clinical Whole-Exome Sequencing."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome, an inborn error of metabolism, is an inherited syndrome caused by loss-of-function mutations in the SLC25A15, resulting in ornithine translocase1 (ORNT1) deficiency."
    explanation: Patient report directly supports SLC25A15 loss of function as the causal molecular defect.
  downstream:
  - target: Mitochondrial Ornithine Transport Defect
    description: Loss of ORC1/ORNT1 function directly impairs mitochondrial ornithine transport.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "HHH syndrome is caused by impaired ornithine transport across the inner mitochondrial membrane due to mutations in SLC25A15 gene, which encodes for the mitochondrial ornithine carrier ORC1."
      explanation: The HHH systematic review directly links SLC25A15 variants to impaired mitochondrial ornithine transport.
- name: Mitochondrial Ornithine Transport Defect
  description: >-
    Defective ORC1 transport prevents normal movement of ornithine into
    mitochondria, disrupting the mitochondrial entry point needed for
    ornithine-dependent urea-cycle flux.
  biological_processes:
  - preferred_term: ornithine transport
    term:
      id: GO:0015822
      label: ornithine transport
    modifier: DECREASED
  cellular_components:
  - preferred_term: mitochondrial inner membrane
    term:
      id: GO:0005743
      label: mitochondrial inner membrane
  chemical_entities:
  - preferred_term: ornithine
    term:
      id: CHEBI:18257
      label: ornithine
    modifier: INCREASED
  evidence:
  - reference: PMID:25874378
    reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HHH syndrome is caused by impaired ornithine transport across the inner mitochondrial membrane due to mutations in SLC25A15 gene, which encodes for the mitochondrial ornithine carrier ORC1."
    explanation: Directly supports the mitochondrial ornithine transport defect.
  - reference: PMID:36506307
    reference_title: "Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HHH is caused by biallelic disease-causing variants in the SLC25A15 gene."
    explanation: Cohort evidence supports biallelic SLC25A15 variants as the driver of the transport defect.
  downstream:
  - target: Hyperornithinemia
    description: Impaired mitochondrial ornithine entry causes systemic ornithine accumulation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39597062
      reference_title: "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome in Vietnamese Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Ornithine carrier 1 deficiency causes HHH syndrome, characterized by failure of mitochondrial ornithine uptake, hyperammonemia, and accumulation of ornithine and lysine in the cytoplasm."
      explanation: Human cohort report links failure of mitochondrial ornithine uptake to ornithine accumulation.
  - target: Chorioretinal atrophy
    description: Rare ocular involvement is reported in the HHH phenotype spectrum and is linked here to the chronic hyperornithinemic transport-defect state.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0000533 | Chorioretinal atrophy | Very rare (<4-1%)"
      explanation: Orphanet records chorioretinal atrophy as a rare HHH phenotype.
  - target: Chorioretinal hypopigmentation
    description: Rare chorioretinal hypopigmentation is represented as ocular involvement downstream of the chronic ornithine transport defect.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0040030 | Chorioretinal hypopigmentation | Very rare (<4-1%)"
      explanation: Orphanet records chorioretinal hypopigmentation as a rare HHH phenotype.
  - target: Urea Cycle Flux Impairment
    description: Mitochondrial ornithine deficiency reduces ornithine-dependent urea-cycle flux.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "HHH syndrome enters in the differential diagnosis with other inherited or acquired conditions presenting with hyperammonemia."
      explanation: HHH behaves as a urea-cycle hyperammonemia disorder because ornithine transport is required for normal flux.
- name: Urea Cycle Flux Impairment
  description: >-
    Reduced mitochondrial ornithine availability functionally impairs the urea
    cycle, lowering hepatic nitrogen disposal and producing hyperammonemia.
  biological_processes:
  - preferred_term: urea cycle
    term:
      id: GO:0000050
      label: urea cycle
    modifier: DECREASED
  chemical_entities:
  - preferred_term: ammonia
    term:
      id: CHEBI:16134
      label: ammonia
    modifier: INCREASED
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:25874378
    reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BACKGROUND: Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome is a rare autosomal recessive disorder of the urea cycle."
    explanation: The HHH review frames the disorder as a urea-cycle disorder.
  - reference: PMID:30853934
    reference_title: "Hereditary Spastic Paraplegia Is a Common Phenotypic Finding in ARG1 Deficiency, P5CS Deficiency and HHH Syndrome: Three Inborn Errors of Metabolism Caused by Alteration of an Interconnected Pathway of Glutamate and Urea Cycle Metabolism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Interestingly, two urea cycle disorders, Argininemia and Hyperornithinemia-Hyperammonemia-Homocitrullinuria syndrome, are clinically characterized by highly penetrant spastic paraplegia."
    explanation: Review evidence independently identifies HHH syndrome as a urea-cycle disorder.
  downstream:
  - target: Hyperammonemia
    description: Impaired urea-cycle nitrogen disposal produces elevated ammonia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39597062
      reference_title: "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome in Vietnamese Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Ornithine carrier 1 deficiency causes HHH syndrome, characterized by failure of mitochondrial ornithine uptake, hyperammonemia, and accumulation of ornithine and lysine in the cytoplasm."
      explanation: Cohort report directly links ORC1 deficiency to hyperammonemia.
  - target: Hyperammonemic Encephalopathy
    description: Elevated ammonia during impaired urea-cycle flux drives acute encephalopathic decompensation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36506307
      reference_title: "Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The major acute clinical presentation found was encephalopathy and liver dysfunction."
      explanation: Human cohort evidence links HHH metabolic disease to acute encephalopathy.
  - target: Carbamoyl Phosphate Diversion
    description: Reduced ornithine availability leaves carbamoyl phosphate available for diversion into orotic acid and homocitrulline pathways.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced ornithine availability limits normal ornithine transcarbamylase substrate flux.
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The diagnosis relies on clinical signs and the peculiar metabolic triad of hyperammonemia, hyperornithinemia, and urinary excretion of homocitrulline."
      explanation: The diagnostic triad supports a metabolic branch that includes hyperammonemia and homocitrulline production.
  - target: Liver Dysfunction and Coagulation Abnormality
    description: The urea-cycle transport defect is associated with acute and chronic hepatic dysfunction, transaminase elevation, and coagulation abnormalities.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Metabolic decompensation with hepatic nitrogen-disposal stress.
    evidence:
    - reference: PMID:36506307
      reference_title: "Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The major acute clinical presentation found was encephalopathy and liver dysfunction."
      explanation: Cohort evidence supports liver dysfunction as a major presentation in HHH syndrome.
  - target: Respiratory alkalosis
    description: Hyperammonemic urea-cycle decompensation can present with tachypnea and respiratory alkalosis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Hyperventilation during acute hyperammonemic crisis.
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001950 | Respiratory alkalosis | Occasional (29-5%)"
      explanation: Orphanet records respiratory alkalosis in the HHH phenotype spectrum.
  - target: Protein avoidance
    description: Chronic nitrogen intolerance can manifest as aversion to protein-rich foods.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Protein intake increases nitrogen load when urea-cycle flux is impaired.
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Alternatively, patients show a chronic course with aversion for protein rich foods, developmental delay/intellectual disability, myoclonic seizures, ataxia and pyramidal dysfunction."
      explanation: Systematic review supports protein aversion within the chronic HHH phenotype.
  - target: Failure to thrive
    description: Recurrent metabolic stress and chronic protein intolerance contribute to poor growth.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001508 | Failure to thrive | Frequent (79-30%)"
      explanation: Orphanet records failure to thrive as a frequent HHH phenotype.
  - target: Abnormality of citrulline metabolism
    description: Disturbed mitochondrial ornithine entry perturbs urea-cycle intermediate handling, including circulating citrulline.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced ornithine availability alters ornithine transcarbamylase substrate flux and downstream citrulline production.
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0011965 | Abnormality of citrulline metabolism | Very frequent (99-80%)"
      explanation: Orphanet records abnormality of citrulline metabolism as very frequent in HHH syndrome.
- name: Carbamoyl Phosphate Diversion
  description: >-
    When ornithine-dependent mitochondrial flux is impaired, excess carbamoyl
    phosphate is reflected clinically by urinary homocitrulline and often
    orotic acid abnormalities.
  chemical_entities:
  - preferred_term: L-homocitrulline
    term:
      id: CHEBI:17443
      label: L-homocitrulline
    modifier: INCREASED
  - preferred_term: orotic acid
    term:
      id: CHEBI:16742
      label: orotic acid
    modifier: INCREASED
  evidence:
  - reference: PMID:25874378
    reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis relies on clinical signs and the peculiar metabolic triad of hyperammonemia, hyperornithinemia, and urinary excretion of homocitrulline."
    explanation: The systematic review identifies urinary homocitrulline as part of the diagnostic triad.
  - reference: PMID:39597062
    reference_title: "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome in Vietnamese Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three out of four cases presented with hyperammonemia, elevated transaminases, and uraciluria."
    explanation: Vietnamese cohort documents pyrimidine-pathway urinary abnormalities in HHH patients.
  downstream:
  - target: Homocitrullinuria
    description: Carbamoyl-phosphate diversion produces urinary homocitrulline.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The diagnosis relies on clinical signs and the peculiar metabolic triad of hyperammonemia, hyperornithinemia, and urinary excretion of homocitrulline."
      explanation: Directly supports urinary homocitrulline as a biochemical consequence.
  - target: Oroticaciduria
    description: Orotic acid abnormalities can occur as part of the diverted carbamoyl-phosphate state.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0003218 | Oroticaciduria | Frequent (79-30%)"
      explanation: Orphanet records oroticaciduria as a frequent HHH syndrome phenotype.
- name: Hyperammonemic Encephalopathy
  description: >-
    Hyperammonemic crises produce acute encephalopathy with vomiting,
    confusion, lethargy, and coma; recurrent or severe episodes contribute to
    long-term neurologic injury.
  chemical_entities:
  - preferred_term: ammonia
    term:
      id: CHEBI:16134
      label: ammonia
    modifier: INCREASED
  evidence:
  - reference: PMID:25874378
    reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Acute clinical signs include intermittent episodes of vomiting, confusion or coma and hepatitis-like attacks."
    explanation: Systematic review directly describes acute encephalopathic signs in HHH syndrome.
  - reference: PMID:36506307
    reference_title: "Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The major acute clinical presentation found was encephalopathy and liver dysfunction."
    explanation: Cohort evidence identifies encephalopathy as a major acute presentation.
  downstream:
  - target: Acute encephalopathy
    description: Hyperammonemia manifests clinically as acute encephalopathy.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0006846 | Acute encephalopathy | Frequent (79-30%)"
      explanation: Orphanet records acute encephalopathy as a frequent phenotype.
  - target: Lethargy
    description: Acute hyperammonemic encephalopathy can present with lethargy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Lethargy and coma are frequent at disease onset, whereas pyramidal dysfunction and cognitive/behavioural abnormalities represent the most common clinical features in late-onset cases or during the disease course."
      explanation: Systematic review directly links lethargy to acute disease onset.
  - target: Confusion
    description: Hyperammonemic encephalopathy can manifest as episodic confusion.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Acute clinical signs include intermittent episodes of vomiting, confusion or coma and hepatitis-like attacks."
      explanation: Systematic review directly lists confusion among acute clinical signs.
  - target: Coma
    description: Severe acute hyperammonemic encephalopathy can progress to coma.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Acute clinical signs include intermittent episodes of vomiting, confusion or coma and hepatitis-like attacks."
      explanation: Systematic review directly lists coma among acute clinical signs.
  - target: Episodic vomiting
    description: Acute metabolic decompensation includes intermittent vomiting.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Acute clinical signs include intermittent episodes of vomiting, confusion or coma and hepatitis-like attacks."
      explanation: Systematic review directly lists vomiting among acute clinical signs.
  - target: Feeding difficulties
    description: Neonatal or infantile hyperammonemic decompensation can present with poor feeding.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0011968 | Feeding difficulties | Frequent (79-30%)"
      explanation: Orphanet records feeding difficulties as a frequent HHH phenotype.
  - target: Tachypnea
    description: Acute metabolic decompensation can include tachypnea.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002789 | Tachypnea | Frequent (79-30%)"
      explanation: Orphanet records tachypnea as a frequent HHH phenotype.
  - target: Seizure
    description: Hyperammonemic brain dysfunction can include seizures during the HHH disease course.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001250 | Seizure | Occasional (29-5%)"
      explanation: Orphanet records seizures in the HHH phenotype spectrum.
  - target: Generalized myoclonic seizure
    description: Myoclonic seizures occur within the chronic and episodic neurologic HHH phenotype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Alternatively, patients show a chronic course with aversion for protein rich foods, developmental delay/intellectual disability, myoclonic seizures, ataxia and pyramidal dysfunction."
      explanation: Systematic review lists myoclonic seizures in the chronic HHH course.
  - target: Chronic Neurocognitive and Pyramidal Tract Dysfunction
    description: Recurrent metabolic injury and disease-specific mechanisms are associated with chronic neurocognitive and pyramidal tract involvement.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Acute metabolic decompensation.
    - Progressive neurologic involvement described during the disease course.
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Lethargy and coma are frequent at disease onset, whereas pyramidal dysfunction and cognitive/behavioural abnormalities represent the most common clinical features in late-onset cases or during the disease course."
      explanation: The systematic review links acute onset features and chronic neurocognitive/pyramidal involvement.
- name: Chronic Neurocognitive and Pyramidal Tract Dysfunction
  description: >-
    Chronic HHH syndrome commonly involves neurodevelopmental delay, cognitive
    impairment, learning disability, ataxia, spastic paraplegia, hyperreflexia,
    clonus, and other pyramidal signs.
  evidence:
  - reference: PMID:25874378
    reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alternatively, patients show a chronic course with aversion for protein rich foods, developmental delay/intellectual disability, myoclonic seizures, ataxia and pyramidal dysfunction."
    explanation: Systematic review directly supports the chronic neurologic phenotype cluster.
  - reference: PMID:36506307
    reference_title: "Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nervous system involvement was common, progressive, and presented with signs of upper motor neuron disease as well as variable degrees of cognitive impairment."
    explanation: Cohort evidence supports progressive upper-motor-neuron and cognitive involvement.
  downstream:
  - target: Spastic paraplegia
    description: Pyramidal tract involvement can manifest as spastic paraplegia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30853934
      reference_title: "Hereditary Spastic Paraplegia Is a Common Phenotypic Finding in ARG1 Deficiency, P5CS Deficiency and HHH Syndrome: Three Inborn Errors of Metabolism Caused by Alteration of an Interconnected Pathway of Glutamate and Urea Cycle Metabolism."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Hyperornithinemia-Hyperammonemia-Homocitrullinuria syndrome, are clinically characterized by highly penetrant spastic paraplegia."
      explanation: Review evidence supports spastic paraplegia as a prominent HHH syndrome neurologic phenotype.
  - target: Abnormal pyramidal sign
    description: Progressive upper-motor-neuron involvement produces abnormal pyramidal signs.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36506307
      reference_title: "Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Nervous system involvement was common, progressive, and presented with signs of upper motor neuron disease as well as variable degrees of cognitive impairment."
      explanation: Cohort evidence supports upper-motor-neuron signs in HHH syndrome.
  - target: Hyperreflexia
    description: Upper-motor-neuron involvement commonly manifests as hyperreflexia.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001347 | Hyperreflexia | Very frequent (99-80%)"
      explanation: Orphanet records hyperreflexia as a very frequent HHH phenotype.
  - target: Clonus
    description: Pyramidal tract dysfunction can manifest as clonus.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002169 | Clonus | Frequent (79-30%)"
      explanation: Orphanet records clonus as a frequent HHH phenotype.
  - target: Spastic gait
    description: Pyramidal tract dysfunction can produce a spastic gait pattern.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002064 | Spastic gait | Occasional (29-5%)"
      explanation: Orphanet records spastic gait in the HHH phenotype spectrum.
  - target: Cognitive impairment
    description: Progressive neurologic involvement includes variable cognitive impairment.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36506307
      reference_title: "Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Nervous system involvement was common, progressive, and presented with signs of upper motor neuron disease as well as variable degrees of cognitive impairment."
      explanation: Cohort evidence directly links HHH syndrome to cognitive impairment.
  - target: Intellectual disability
    description: Chronic neurocognitive involvement includes developmental delay and intellectual disability.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Alternatively, patients show a chronic course with aversion for protein rich foods, developmental delay/intellectual disability, myoclonic seizures, ataxia and pyramidal dysfunction."
      explanation: Systematic review directly lists developmental delay/intellectual disability in the chronic course.
  - target: Neurodevelopmental delay
    description: Chronic neurologic involvement often includes neurodevelopmental delay.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Alternatively, patients show a chronic course with aversion for protein rich foods, developmental delay/intellectual disability, myoclonic seizures, ataxia and pyramidal dysfunction."
      explanation: Systematic review directly lists developmental delay in the chronic course.
  - target: Specific learning disability
    description: Chronic cognitive involvement can manifest as learning disability.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Chronic neurocognitive impairment.
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001328 | Specific learning disability | Frequent (79-30%)"
      explanation: Orphanet records specific learning disability as a frequent HHH phenotype.
  - target: Progressive cerebellar ataxia
    description: Chronic neurologic involvement includes progressive ataxia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Alternatively, patients show a chronic course with aversion for protein rich foods, developmental delay/intellectual disability, myoclonic seizures, ataxia and pyramidal dysfunction."
      explanation: Systematic review lists ataxia in the chronic HHH course.
  - target: Poor coordination
    description: Cerebellar and motor-system involvement can manifest as poor coordination.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Chronic ataxic motor impairment.
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002370 | Poor coordination | Frequent (79-30%)"
      explanation: Orphanet records poor coordination as a frequent HHH phenotype.
  - target: Generalized hypotonia
    description: Early neurologic involvement can include generalized hypotonia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001290 | Generalized hypotonia | Frequent (79-30%)"
      explanation: Orphanet records generalized hypotonia as a frequent HHH phenotype.
  - target: Impaired vibratory sensation
    description: Chronic neurologic involvement can include sensory pathway impairment.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002495 | Impaired vibratory sensation | Frequent (79-30%)"
      explanation: Orphanet records impaired vibratory sensation as a frequent HHH phenotype.
  - target: Speech apraxia
    description: Chronic neurodevelopmental and motor-planning involvement can manifest as speech apraxia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0011098 | Speech apraxia | Frequent (79-30%)"
      explanation: Orphanet records speech apraxia as a frequent HHH phenotype.
  - target: Cerebral cortical atrophy
    description: Chronic neurologic injury is associated with cerebral cortical atrophy in the HHH phenotype spectrum.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002120 | Cerebral cortical atrophy | Frequent (79-30%)"
      explanation: Orphanet records cerebral cortical atrophy as a frequent HHH phenotype.
  - target: Multifocal cerebral white matter abnormalities
    description: Chronic neurologic disease can include multifocal cerebral white matter abnormalities.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0007052 | Multifocal cerebral white matter abnormalities | Occasional (29-5%)"
      explanation: Orphanet records multifocal cerebral white matter abnormalities in the HHH phenotype spectrum.
- name: Liver Dysfunction and Coagulation Abnormality
  description: >-
    HHH syndrome frequently includes decreased liver function, transaminase
    elevation, hepatitis-like attacks, and coagulation abnormalities; severe
    cases can present with hepatic failure.
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001410 | Decreased liver function | Frequent (79-30%)"
    explanation: Orphanet records decreased liver function as frequent.
  - reference: PMID:36506307
    reference_title: "Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The major acute clinical presentation found was encephalopathy and liver dysfunction."
    explanation: Cohort evidence supports liver dysfunction as a major acute manifestation.
  downstream:
  - target: Decreased liver function
    description: Hepatic involvement manifests as decreased liver function.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001410 | Decreased liver function | Frequent (79-30%)"
      explanation: Orphanet records decreased liver function as a frequent HHH phenotype.
  - target: Hepatitis
    description: HHH hepatic involvement can include hepatitis-like attacks.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Acute clinical signs include intermittent episodes of vomiting, confusion or coma and hepatitis-like attacks."
      explanation: Systematic review lists hepatitis-like attacks among acute HHH signs.
  - target: Hepatic failure
    description: Severe hepatic involvement can progress to hepatic failure in rare cases.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0001399 | Hepatic failure | Very rare (<4-1%)"
      explanation: Orphanet records hepatic failure as a rare HHH phenotype.
  - target: Hepatomegaly
    description: Hepatic involvement can manifest as hepatomegaly.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002240 | Hepatomegaly | Frequent (79-30%)"
      explanation: Orphanet records hepatomegaly as a frequent HHH phenotype.
  - target: Elevated circulating hepatic transaminase concentration
    description: Liver injury in HHH syndrome is reflected by elevated circulating hepatic transaminases.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39597062
      reference_title: "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome in Vietnamese Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Three out of four cases presented with hyperammonemia, elevated transaminases, and uraciluria."
      explanation: Human cohort data document elevated transaminases in HHH presentations.
  - target: Elevated hepatic transaminases
    description: Elevated hepatic transaminases provide a biochemical readout of the liver-dysfunction branch.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39597062
      reference_title: "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome in Vietnamese Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Three out of four cases presented with hyperammonemia, elevated transaminases, and uraciluria."
      explanation: Human cohort data document elevated transaminases in HHH presentations.
  - target: Abnormality of the coagulation cascade
    description: Hepatic dysfunction can be accompanied by coagulation abnormalities.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced hepatic synthetic function.
    evidence:
    - reference: PMID:39597062
      reference_title: "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome in Vietnamese Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "All four cases demonstrated hyperornithinemia and prolonged prothrombin time."
      explanation: Human cohort data support a coagulation abnormality accompanying HHH syndrome.
phenotypes:
- name: Chorioretinal atrophy
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Chorioretinal atrophy
    term:
      id: HP:0000533
      label: Chorioretinal atrophy
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000533 | Chorioretinal atrophy | Very rare (<4-1%)"
    explanation: Orphanet lists chorioretinal atrophy as a very rare HHH syndrome phenotype.
- name: Intellectual disability
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001249 | Intellectual disability | Frequent (79-30%)"
    explanation: Orphanet lists intellectual disability as a frequent phenotype.
- name: Seizure
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001250 | Seizure | Occasional (29-5%)"
    explanation: Orphanet lists seizure as an occasional phenotype.
- name: Lethargy
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Lethargy
    term:
      id: HP:0001254
      label: Lethargy
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001254 | Lethargy | Frequent (79-30%)"
    explanation: Orphanet lists lethargy as a frequent phenotype.
- name: Spastic paraplegia
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Spastic paraplegia
    term:
      id: HP:0001258
      label: Spastic paraplegia
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001258 | Spastic paraplegia | Frequent (79-30%)"
    explanation: Orphanet lists spastic paraplegia as a frequent phenotype.
  - reference: PMID:30853934
    reference_title: "Hereditary Spastic Paraplegia Is a Common Phenotypic Finding in ARG1 Deficiency, P5CS Deficiency and HHH Syndrome: Three Inborn Errors of Metabolism Caused by Alteration of an Interconnected Pathway of Glutamate and Urea Cycle Metabolism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hyperornithinemia-Hyperammonemia-Homocitrullinuria syndrome, are clinically characterized by highly penetrant spastic paraplegia."
    explanation: Literature review supports spastic paraplegia as a prominent clinical phenotype.
- name: Coma
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Coma
    term:
      id: HP:0001259
      label: Coma
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001259 | Coma | Occasional (29-5%)"
    explanation: Orphanet lists coma as an occasional phenotype.
- name: Confusion
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Confusion
    term:
      id: HP:0001289
      label: Confusion
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001289 | Confusion | Frequent (79-30%)"
    explanation: Orphanet lists confusion as a frequent phenotype.
- name: Generalized hypotonia
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Generalized hypotonia
    term:
      id: HP:0001290
      label: Generalized hypotonia
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001290 | Generalized hypotonia | Frequent (79-30%)"
    explanation: Orphanet lists generalized hypotonia as a frequent phenotype.
- name: Specific learning disability
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Specific learning disability
    term:
      id: HP:0001328
      label: Specific learning disability
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001328 | Specific learning disability | Frequent (79-30%)"
    explanation: Orphanet lists specific learning disability as a frequent phenotype.
- name: Hyperreflexia
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hyperreflexia
    term:
      id: HP:0001347
      label: Hyperreflexia
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001347 | Hyperreflexia | Very frequent (99-80%)"
    explanation: Orphanet lists hyperreflexia as a very frequent phenotype.
- name: Hepatic failure
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Hepatic failure
    term:
      id: HP:0001399
      label: Hepatic failure
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001399 | Hepatic failure | Very rare (<4-1%)"
    explanation: Orphanet lists hepatic failure as a very rare phenotype.
- name: Decreased liver function
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Decreased liver function
    term:
      id: HP:0001410
      label: Decreased liver function
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001410 | Decreased liver function | Frequent (79-30%)"
    explanation: Orphanet lists decreased liver function as a frequent phenotype.
- name: Failure to thrive
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001508 | Failure to thrive | Frequent (79-30%)"
    explanation: Orphanet lists failure to thrive as a frequent phenotype.
- name: Respiratory alkalosis
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Respiratory alkalosis
    term:
      id: HP:0001950
      label: Respiratory alkalosis
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001950 | Respiratory alkalosis | Occasional (29-5%)"
    explanation: Orphanet lists respiratory alkalosis as an occasional phenotype.
- name: Hyperammonemia
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001987 | Hyperammonemia | Very frequent (99-80%)"
    explanation: Orphanet lists hyperammonemia as a very frequent phenotype.
  - reference: PMID:39597062
    reference_title: "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome in Vietnamese Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three out of four cases presented with hyperammonemia, elevated transaminases, and uraciluria."
    explanation: Human cohort data support hyperammonemia as a common biochemical-clinical feature.
- name: Protein avoidance
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Protein avoidance
    term:
      id: HP:0002038
      label: Protein avoidance
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002038 | Protein avoidance | Frequent (79-30%)"
    explanation: Orphanet lists protein avoidance as a frequent phenotype.
- name: Spastic gait
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Spastic gait
    term:
      id: HP:0002064
      label: Spastic gait
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002064 | Spastic gait | Occasional (29-5%)"
    explanation: Orphanet lists spastic gait as an occasional phenotype.
- name: Progressive cerebellar ataxia
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Progressive cerebellar ataxia
    term:
      id: HP:0002073
      label: Progressive cerebellar ataxia
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002073 | Progressive cerebellar ataxia | Frequent (79-30%)"
    explanation: Orphanet lists progressive cerebellar ataxia as a frequent phenotype.
- name: Cerebral cortical atrophy
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Cerebral cortical atrophy
    term:
      id: HP:0002120
      label: Cerebral cortical atrophy
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002120 | Cerebral cortical atrophy | Frequent (79-30%)"
    explanation: Orphanet lists cerebral cortical atrophy as a frequent phenotype.
- name: Generalized myoclonic seizure
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Generalized myoclonic seizure
    term:
      id: HP:0002123
      label: Generalized myoclonic seizure
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002123 | Generalized myoclonic seizure | Occasional (29-5%)"
    explanation: Orphanet lists generalized myoclonic seizure as an occasional phenotype.
- name: Clonus
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Clonus
    term:
      id: HP:0002169
      label: Clonus
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002169 | Clonus | Frequent (79-30%)"
    explanation: Orphanet lists clonus as a frequent phenotype.
- name: Hepatomegaly
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002240 | Hepatomegaly | Frequent (79-30%)"
    explanation: Orphanet lists hepatomegaly as a frequent phenotype.
- name: Poor coordination
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Poor coordination
    term:
      id: HP:0002311
      label: Incoordination
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002370 | Poor coordination | Frequent (79-30%)"
    explanation: Orphanet lists poor coordination as a frequent phenotype; the obsolete HPO row is represented with the current Incoordination term whose synonyms include poor coordination.
- name: Impaired vibratory sensation
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Impaired vibratory sensation
    term:
      id: HP:0002495
      label: Impaired vibratory sensation
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002495 | Impaired vibratory sensation | Frequent (79-30%)"
    explanation: Orphanet lists impaired vibratory sensation as a frequent phenotype.
- name: Episodic vomiting
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Episodic vomiting
    term:
      id: HP:0002572
      label: Episodic vomiting
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002572 | Episodic vomiting | Frequent (79-30%)"
    explanation: Orphanet lists episodic vomiting as a frequent phenotype.
- name: Tachypnea
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Tachypnea
    term:
      id: HP:0002789
      label: Tachypnea
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002789 | Tachypnea | Frequent (79-30%)"
    explanation: Orphanet lists tachypnea as a frequent phenotype.
- name: Elevated circulating hepatic transaminase concentration
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Elevated circulating hepatic transaminase concentration
    term:
      id: HP:0002910
      label: Elevated circulating hepatic transaminase concentration
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002910 | Elevated circulating hepatic transaminase concentration | Frequent (79-30%)"
    explanation: Orphanet lists elevated circulating hepatic transaminase concentration as a frequent phenotype.
- name: Oroticaciduria
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Oroticaciduria
    term:
      id: HP:0003218
      label: Oroticaciduria
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003218 | Oroticaciduria | Frequent (79-30%)"
    explanation: Orphanet lists oroticaciduria as a frequent phenotype.
- name: Abnormality of the coagulation cascade
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Abnormality of the coagulation cascade
    term:
      id: HP:0003256
      label: Abnormality of the coagulation cascade
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003256 | Abnormality of the coagulation cascade | Occasional (29-5%)"
    explanation: Orphanet lists coagulation-cascade abnormality as an occasional phenotype.
- name: Acute encephalopathy
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Acute encephalopathy
    term:
      id: HP:0006846
      label: Acute encephalopathy
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0006846 | Acute encephalopathy | Frequent (79-30%)"
    explanation: Orphanet lists acute encephalopathy as a frequent phenotype.
  - reference: PMID:36506307
    reference_title: "Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The major acute clinical presentation found was encephalopathy and liver dysfunction."
    explanation: Cohort evidence supports acute encephalopathy as a major presentation.
- name: Multifocal cerebral white matter abnormalities
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Multifocal cerebral white matter abnormalities
    term:
      id: HP:0007052
      label: Multifocal cerebral white matter abnormalities
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007052 | Multifocal cerebral white matter abnormalities | Occasional (29-5%)"
    explanation: Orphanet lists multifocal cerebral white matter abnormalities as an occasional phenotype.
- name: Abnormal pyramidal sign
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Abnormal pyramidal sign
    term:
      id: HP:0007256
      label: Abnormal pyramidal sign
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007256 | Abnormal pyramidal sign | Frequent (79-30%)"
    explanation: Orphanet lists abnormal pyramidal sign as a frequent phenotype.
- name: Speech apraxia
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Speech apraxia
    term:
      id: HP:0011098
      label: Speech apraxia
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0011098 | Speech apraxia | Frequent (79-30%)"
    explanation: Orphanet lists speech apraxia as a frequent phenotype.
- name: Abnormality of citrulline metabolism
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Abnormality of citrulline metabolism
    term:
      id: HP:0011965
      label: Abnormal circulating citrulline concentration
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0011965 | Abnormality of citrulline metabolism | Very frequent (99-80%)"
    explanation: Orphanet lists abnormality of citrulline metabolism as a very frequent phenotype.
- name: Feeding difficulties
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0011968 | Feeding difficulties | Frequent (79-30%)"
    explanation: Orphanet lists feeding difficulties as a frequent phenotype.
- name: Hyperornithinemia
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hyperornithinemia
    term:
      id: HP:0012026
      label: Hyperornithinemia
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012026 | Hyperornithinemia | Very frequent (99-80%)"
    explanation: Orphanet lists hyperornithinemia as a very frequent phenotype.
  - reference: PMID:39597062
    reference_title: "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome in Vietnamese Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All four cases demonstrated hyperornithinemia and prolonged prothrombin time."
    explanation: Vietnamese cohort data support hyperornithinemia as a consistent biochemical feature in that cohort.
- name: Hepatitis
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hepatitis
    term:
      id: HP:0012115
      label: Hepatitis
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012115 | Hepatitis | Frequent (79-30%)"
    explanation: Orphanet lists hepatitis as a frequent phenotype.
- name: Neurodevelopmental delay
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Neurodevelopmental delay
    term:
      id: HP:0012758
      label: Neurodevelopmental delay
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012758 | Neurodevelopmental delay | Very frequent (99-80%)"
    explanation: Orphanet lists neurodevelopmental delay as a very frequent phenotype.
- name: Chorioretinal hypopigmentation
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Chorioretinal hypopigmentation
    term:
      id: HP:0040030
      label: Chorioretinal hypopigmentation
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0040030 | Chorioretinal hypopigmentation | Very rare (<4-1%)"
    explanation: Orphanet lists chorioretinal hypopigmentation as a very rare phenotype.
- name: Cognitive impairment
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0100543 | Cognitive impairment | Very frequent (99-80%)"
    explanation: Orphanet lists cognitive impairment as a very frequent phenotype.
  - reference: PMID:36506307
    reference_title: "Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nervous system involvement was common, progressive, and presented with signs of upper motor neuron disease as well as variable degrees of cognitive impairment."
    explanation: Cohort evidence directly supports cognitive impairment.
biochemical:
- name: Hyperornithinemia
  presence: INCREASED
  frequency: VERY_FREQUENT
  context: >-
    Elevated plasma ornithine is a defining biochemical feature of HHH syndrome
    and reflects failure of mitochondrial ornithine uptake.
  biomarker_term:
    preferred_term: ornithine
    term:
      id: CHEBI:18257
      label: ornithine
  readouts:
  - target: Mitochondrial Ornithine Transport Defect
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated ornithine reports failed mitochondrial ornithine uptake due to ORC1/ORNT1 transport deficiency.
    evidence:
    - reference: PMID:39597062
      reference_title: "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome in Vietnamese Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Ornithine carrier 1 deficiency causes HHH syndrome, characterized by failure of mitochondrial ornithine uptake, hyperammonemia, and accumulation of ornithine and lysine in the cytoplasm."
      explanation: Human cohort evidence directly connects failed mitochondrial ornithine uptake to ornithine accumulation.
  evidence:
  - reference: PMID:39597062
    reference_title: "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome in Vietnamese Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All four cases demonstrated hyperornithinemia and prolonged prothrombin time."
    explanation: Cohort data document hyperornithinemia.
- name: Hyperammonemia
  presence: INCREASED
  frequency: VERY_FREQUENT
  context: >-
    Elevated ammonia is a core biochemical abnormality and the driver of acute
    metabolic encephalopathy.
  biomarker_term:
    preferred_term: ammonia
    term:
      id: CHEBI:16134
      label: ammonia
  readouts:
  - target: Urea Cycle Flux Impairment
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated ammonia reports impaired hepatic urea-cycle nitrogen disposal.
    evidence:
    - reference: PMID:39597062
      reference_title: "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome in Vietnamese Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Three out of four cases presented with hyperammonemia, elevated transaminases, and uraciluria."
      explanation: Human cohort data support hyperammonemia as a biochemical readout of the impaired urea-cycle branch.
  evidence:
  - reference: PMID:39597062
    reference_title: "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome in Vietnamese Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three out of four cases presented with hyperammonemia, elevated transaminases, and uraciluria."
    explanation: Human cohort data support increased ammonia.
- name: Homocitrullinuria
  presence: INCREASED
  context: >-
    Urinary homocitrulline is part of the characteristic diagnostic triad,
    although some modern cohorts report incomplete expression.
  biomarker_term:
    preferred_term: L-homocitrulline
    term:
      id: CHEBI:17443
      label: L-homocitrulline
  readouts:
  - target: Carbamoyl Phosphate Diversion
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Urinary homocitrulline reports carbamoyl-phosphate diversion when ornithine-dependent urea-cycle flux is impaired.
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The diagnosis relies on clinical signs and the peculiar metabolic triad of hyperammonemia, hyperornithinemia, and urinary excretion of homocitrulline."
      explanation: The diagnostic triad supports urinary homocitrulline as a readout of the diverted urea-cycle intermediate state.
  evidence:
  - reference: PMID:25874378
    reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis relies on clinical signs and the peculiar metabolic triad of hyperammonemia, hyperornithinemia, and urinary excretion of homocitrulline."
    explanation: Systematic review identifies urinary homocitrulline as part of the diagnostic triad.
- name: Oroticaciduria
  presence: INCREASED
  frequency: FREQUENT
  context: >-
    Oroticaciduria or related urinary pyrimidine abnormalities can occur as a
    secondary biochemical marker of carbamoyl phosphate diversion.
  biomarker_term:
    preferred_term: orotic acid
    term:
      id: CHEBI:16742
      label: orotic acid
  readouts:
  - target: Carbamoyl Phosphate Diversion
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Oroticaciduria reports diversion of excess carbamoyl phosphate into pyrimidine-pathway products.
    evidence:
    - reference: ORPHA:415
      reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0003218 | Oroticaciduria | Frequent (79-30%)"
      explanation: Orphanet supports oroticaciduria as a frequent biochemical manifestation of the carbamoyl-phosphate diversion branch.
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003218 | Oroticaciduria | Frequent (79-30%)"
    explanation: Orphanet records oroticaciduria as frequent.
- name: Elevated hepatic transaminases
  presence: INCREASED
  frequency: FREQUENT
  context: >-
    Elevated hepatic transaminases accompany liver dysfunction during acute or
    chronic HHH syndrome presentations.
  readouts:
  - target: Liver Dysfunction and Coagulation Abnormality
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: Elevated hepatic transaminases report the liver-dysfunction branch of HHH syndrome.
    evidence:
    - reference: PMID:39597062
      reference_title: "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome in Vietnamese Patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Three out of four cases presented with hyperammonemia, elevated transaminases, and uraciluria."
      explanation: Human cohort data directly document elevated transaminases accompanying HHH presentations.
  evidence:
  - reference: PMID:39597062
    reference_title: "Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome in Vietnamese Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three out of four cases presented with hyperammonemia, elevated transaminases, and uraciluria."
    explanation: Cohort data document elevated transaminases.
genetic:
- name: SLC25A15 pathogenic variants
  gene_term:
    preferred_term: SLC25A15
    term:
      id: hgnc:10985
      label: SLC25A15
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:36506307
      reference_title: "Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "HHH is caused by biallelic disease-causing variants in the SLC25A15 gene."
      explanation: Cohort evidence identifies biallelic SLC25A15 variants as causal.
  variants:
  - name: SLC25A15 c.552-555delTTTC
    description: >-
      Novel homozygous exon 5 frameshift deletion reported in nine Palestinian
      patients with HHH syndrome.
    evidence:
    - reference: PMID:36506307
      reference_title: "Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Analysis of the SLC25A15 gene sequence revealed a novel homozygous frameshift deletion in exon 5, NM_014252.4:c.552-555delTTTC; p (Phe185SerfsTer8) in nine patients."
      explanation: Cohort report documents this recurrent novel frameshift deletion.
  - name: SLC25A15 c.446delG
    description: >-
      Recurrent homozygous frameshift variant reported in Palestinian patients
      with HHH syndrome.
    evidence:
    - reference: PMID:36506307
      reference_title: "Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The remaining four patients had a recurrent homozygous frameshift variant; NM_014252.4:c.446delG, (p.Ser149ThrfsTer45)."
      explanation: Cohort report documents this recurrent frameshift variant.
  - name: SLC25A15 codon 21 and 179 variants
    description: >-
      Compound heterozygous SLC25A15 variants predicted to cause ORNT1 loss of
      function in a child diagnosed by whole-exome sequencing.
    evidence:
    - reference: PMID:39086438
      reference_title: "A Novel Mutation of ORNT1 Detected in a Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome Child by Clinical Whole-Exome Sequencing."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "After biochemical confirmation of HHH, whole-exome sequencing (WES) was performed, which identified mutations at codons 21 and 179 of SLC25A15 that are predicted to result in the loss of function of ORNT1."
      explanation: Case report documents compound heterozygous variants predicted to disrupt ORNT1.
  features: >-
    Biallelic pathogenic SLC25A15 variants cause ORC1/ORNT1 loss of function.
    Reported variants include recurrent frameshift changes and variants such as
    p.Arg179* and p.Phe188del in different populations. Genotype-phenotype
    correlation is incomplete.
  evidence:
  - reference: ORPHA:415
    reference_title: "Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SLC25A15 | solute carrier family 25 member 15 | hgnc:10985 | Disease-causing germline mutation(s) (loss of function) in"
    explanation: Orphanet identifies SLC25A15 loss-of-function germline variants as causal.
  - reference: PMID:36506307
    reference_title: "Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There was no clear genotype-phenotype correlation."
    explanation: Cohort data support incomplete genotype-phenotype correlation.
diagnosis:
- name: Biochemical triad testing
  description: >-
    Plasma ammonia and ornithine testing together with urine homocitrulline
    detection supports HHH syndrome diagnosis and distinguishes it from other
    inherited or acquired hyperammonemia disorders.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  evidence:
  - reference: PMID:25874378
    reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis relies on clinical signs and the peculiar metabolic triad of hyperammonemia, hyperornithinemia, and urinary excretion of homocitrulline."
    explanation: Systematic review directly states the diagnostic biochemical triad.
- name: SLC25A15 molecular genetic testing
  description: >-
    Molecular testing confirms biallelic SLC25A15 pathogenic variants, supports
    family-based risk assessment, and can accelerate diagnosis when clinical
    and biochemical features are nonspecific.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: MAXO:0000127
      label: genetic testing
  evidence:
  - reference: PMID:39086438
    reference_title: "A Novel Mutation of ORNT1 Detected in a Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome Child by Clinical Whole-Exome Sequencing."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Furthermore, performing a WES provides a shortcut for accurate diagnosis."
    explanation: Case report supports whole-exome sequencing as a route to accurate HHH syndrome diagnosis.
treatments:
- name: Protein-restricted diet
  description: >-
    Chronic dietary protein restriction lowers nitrogen load and is a core
    long-term strategy for controlling hyperammonemia.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  target_mechanisms:
  - target: Urea Cycle Flux Impairment
    treatment_effect: MODULATES
    description: Dietary nitrogen reduction decreases the burden on impaired urea-cycle flux.
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Acute and chronic management consists in the control of hyperammonemia with protein-restricted diet supplemented with citrulline/arginine and ammonia scavengers."
      explanation: Review evidence directly supports protein restriction as part of acute and chronic management.
  target_phenotypes:
  - preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  evidence:
  - reference: PMID:25874378
    reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Acute and chronic management consists in the control of hyperammonemia with protein-restricted diet supplemented with citrulline/arginine and ammonia scavengers."
    explanation: Systematic review identifies protein-restricted diet as part of HHH syndrome management.
- name: Citrulline and arginine supplementation
  description: >-
    Citrulline or arginine supplementation is used with dietary management to
    support urea-cycle intermediate availability and biochemical control.
  treatment_term:
    preferred_term: nutritional supplementation
    term:
      id: MAXO:0000106
      label: nutritional supplementation
    therapeutic_agent:
    - preferred_term: citrulline
      term:
        id: CHEBI:18211
        label: citrulline
    - preferred_term: L-arginine
      term:
        id: CHEBI:16467
        label: L-arginine
  target_mechanisms:
  - target: Urea Cycle Flux Impairment
    treatment_effect: MODULATES
    description: Citrulline or arginine supplementation supports residual urea-cycle flux.
    evidence:
    - reference: PMID:25874378
      reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Acute and chronic management consists in the control of hyperammonemia with protein-restricted diet supplemented with citrulline/arginine and ammonia scavengers."
      explanation: Review evidence directly supports citrulline/arginine supplementation in HHH syndrome management.
  target_phenotypes:
  - preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  evidence:
  - reference: PMID:25874378
    reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Acute and chronic management consists in the control of hyperammonemia with protein-restricted diet supplemented with citrulline/arginine and ammonia scavengers."
    explanation: Systematic review identifies citrulline/arginine supplementation as part of management.
- name: Ammonia scavenger therapy
  description: >-
    Ammonia scavengers are used to control ammonia in HHH syndrome, providing
    alternative nitrogen-disposal routes when urea-cycle flux is impaired.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: sodium benzoate
      term:
        id: CHEBI:113455
        label: sodium benzoate
    - preferred_term: sodium phenylbutyrate
      term:
        id: CHEBI:75316
        label: sodium phenylbutyrate
  target_mechanisms:
  - target: Urea Cycle Flux Impairment
    treatment_effect: BYPASSES
    description: Ammonia scavengers bypass impaired ureagenesis through alternative urinary nitrogen-disposal pathways.
    evidence:
    - reference: PMID:33409766
      reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Ammonia is diverted to the glycine and hippuric acid pathway by benzoate, and to the glutamine and phenylacetylglutamine pathway allowing elimination in the urine without passing through the urea cycle"
      explanation: UCD management review supports the bypass mechanism for benzoate and phenylbutyrate-related scavenger therapy.
  target_phenotypes:
  - preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  evidence:
  - reference: PMID:25874378
    reference_title: "The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Acute and chronic management consists in the control of hyperammonemia with protein-restricted diet supplemented with citrulline/arginine and ammonia scavengers."
    explanation: HHH syndrome review identifies ammonia scavengers as part of management.
  - reference: PMID:33409766
    reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ammonia is diverted to the glycine and hippuric acid pathway by benzoate, and to the glutamine and phenylacetylglutamine pathway allowing elimination in the urine without passing through the urea cycle"
    explanation: UCD management review names benzoate and the phenylacetylglutamine pathway underlying phenylbutyrate therapy.
- name: Acute hyperammonemic crisis management
  description: >-
    Acute metabolic decompensation requires urgent correction of ammonia and
    metabolite imbalances to reduce risk of irreversible neurologic injury.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_mechanisms:
  - target: Hyperammonemic Encephalopathy
    treatment_effect: INHIBITS
    description: Rapid ammonia and metabolite correction reduces the encephalopathy cascade.
    evidence:
    - reference: PMID:39086438
      reference_title: "A Novel Mutation of ORNT1 Detected in a Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome Child by Clinical Whole-Exome Sequencing."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Correction of the accumulating metabolites is necessary to prevent irreversible neurological impairment."
      explanation: Case report directly supports urgent correction of accumulating metabolites to prevent neurologic injury.
  target_phenotypes:
  - preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  - preferred_term: Acute encephalopathy
    term:
      id: HP:0006846
      label: Acute encephalopathy
  evidence:
  - reference: PMID:39086438
    reference_title: "A Novel Mutation of ORNT1 Detected in a Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome Child by Clinical Whole-Exome Sequencing."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Correction of the accumulating metabolites is necessary to prevent irreversible neurological impairment."
    explanation: HHH case report supports acute metabolic correction as necessary to prevent irreversible neurologic sequelae.
notes: >-
  The Asta literature retrieval completed and identified the core HHH systematic
  review, recent human cohorts, case reports, and pregnancy-management review.
  The diabetes-focused Asta result PMID:39982365 was excluded as off target.
clinical_trials: []
datasets: []
references:
- reference: ORPHA:415
  title: Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome
  found_in:
  - Hyperornithinemia_Hyperammonemia_Homocitrullinuria_Syndrome-deep-research-asta.md
- reference: PMID:25874378
  title: The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome.
  found_in:
  - Hyperornithinemia_Hyperammonemia_Homocitrullinuria_Syndrome-deep-research-asta.md
- reference: PMID:36506307
  title: Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene.
  found_in:
  - Hyperornithinemia_Hyperammonemia_Homocitrullinuria_Syndrome-deep-research-asta.md
- reference: PMID:39086438
  title: A Novel Mutation of ORNT1 Detected in a Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome Child by Clinical Whole-Exome Sequencing.
  found_in:
  - Hyperornithinemia_Hyperammonemia_Homocitrullinuria_Syndrome-deep-research-asta.md
- reference: PMID:39597062
  title: Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome in Vietnamese Patients.
  found_in:
  - Hyperornithinemia_Hyperammonemia_Homocitrullinuria_Syndrome-deep-research-asta.md
- reference: PMID:30853934
  title: "Hereditary Spastic Paraplegia Is a Common Phenotypic Finding in ARG1 Deficiency, P5CS Deficiency and HHH Syndrome: Three Inborn Errors of Metabolism Caused by Alteration of an Interconnected Pathway of Glutamate and Urea Cycle Metabolism."
  found_in:
  - Hyperornithinemia_Hyperammonemia_Homocitrullinuria_Syndrome-deep-research-asta.md
- reference: PMID:33409766
  title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
  found_in:
  - Hyperornithinemia_Hyperammonemia_Homocitrullinuria_Syndrome-deep-research-asta.md
📚

References & Deep Research

References

7
ORPHA:415
Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome
No top-level findings curated for this source.
PMID:25874378
The hyperornithinemia-hyperammonemia-homocitrullinuria syndrome.
No top-level findings curated for this source.
PMID:36506307
Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene.
No top-level findings curated for this source.
PMID:39086438
A Novel Mutation of ORNT1 Detected in a Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome Child by Clinical Whole-Exome Sequencing.
No top-level findings curated for this source.
PMID:39597062
Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome in Vietnamese Patients.
No top-level findings curated for this source.
PMID:30853934
Hereditary Spastic Paraplegia Is a Common Phenotypic Finding in ARG1 Deficiency, P5CS Deficiency and HHH Syndrome: Three Inborn Errors of Metabolism Caused by Alteration of an Interconnected Pathway of Glutamate and Urea Cycle Metabolism.
No top-level findings curated for this source.
PMID:33409766
Management of late onset urea cycle disorders-a remaining challenge for the intensivist?
No top-level findings curated for this source.

Deep Research

1
Asta ▸
Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome. Core disease...
Asta Scientific Corpus Retrieval 13 citations 2026-05-11T00:41:25.744115

Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome. Core disease...

This report is retrieval-only and is generated directly from Asta results.

  • Papers retrieved: 13
  • Snippets retrieved: 19

Relevant Papers

[1] A Novel Mutation of ORNT1 Detected in a Hyperornithinemia–Hyperammonemia–Homocitrullinuria Syndrome Child by Clinical Whole-Exome Sequencing

  • Authors: Wison Laochareonsuk, S. Osatakul, U. Intusoma, Wanwisa Maneechay, S. Sangkhathat
  • Year: 2021
  • Venue: Journal of Pediatric Genetics
  • URL: https://www.semanticscholar.org/paper/fbdfc43fe477092a1d7af79af2f3d1c9eff2de38
  • DOI: 10.1055/s-0041-1742247
  • PMID: 39086438
  • PMCID: 11288712
  • Summary: A compound heterozygous mutation in SLC25A15 from a 2-year-old girl who presented with neurological alterations and hepatic failure is reported, which identified mutations that are predicted to result in the loss of function of ORNT1.
  • Evidence snippets:
  • Snippet 1 (score: 0.577) > Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome is a rare hereditary urea cycle disorder (UCD) found in approximately 1:2,000,000 livebirths. 1 The syndrome is caused by an ornithine translocase1 (ORNT1) deficiency secondary to homozygous or compound heterozygous mutations that result in the loss of function of the SLC25A15 gene. 2 Ornithine is an intermediate metabolite in the urea cycle which transfers carbamoyl phosphate from the mitochondrial matrix to the cytosol. Defects of ORNT1 disrupt ornithine and citrulline transportation, leading to the accumulation of the precursor substrates in the plasma, as well as ornithine and ammonia, and retained carbamoyl phosphate is alternatively converted to homocitrulline and excreted through the urine. 3 s a result of episodic increases of plasma ammonia, an affected individual can present at various ages of onset with a wide spectrum of manifestations including protein-rich diet intolerance, neurological impairment, and hepatitis. 4,5 To prevent sequelae of ammonia toxicity, acute treatment is required, especially prompt reduction of plasma ammonia and correction of metabolite imbalances. For maintenance therapy, recommendations include a low-protein diet combined with essential amino acid supplements such as citrulline or arginine to archive biochemical control. In addition, some patients will need ammonia scavengers including sodium benzoate or sodium phenylbutyrate to maintain appropriate serum ammonia. 6 Long-term neurological outcomes vary from mild intellectual disturbances to severe disability. > Because of rapidly decreasing costs and increasing accuracy of high throughput technology, clinical whole-exome sequencing (WES) can potentially help clinicians to provide a timely diagnosis and appropriate treatment for rare pediatric diseases. Early diagnosis of an inborn error of metabolism leads to prompt implementation of appropriate metabolic control which improves long-term clinical outcomes. > In this case report, we described a girl with HHH syndrome who presented with neurological alterations and hepatic failure at the age of 2 years. Clinical WES comprehensively annotated the whole panel of genes involved in her UCDs.

[2] Immune Alterations in a Patient With Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome: A Case Report

  • Authors: Silene M. Silvera-Ruiz, C. Gemperle, Natalia Peano, Valentina Olivero, Adriana Becerra et al.
  • Year: 2022
  • Venue: Frontiers in Immunology
  • URL: https://www.semanticscholar.org/paper/7b744a7e101c2b486c721732c26da2fb9ba712d3
  • DOI: 10.3389/fimmu.2022.861516
  • PMID: 35711415
  • PMCID: 9196877
  • Citations: 5
  • Summary: This study has identified two non-previously described mutations in the SLC25A15 gene underlying the HHH syndrome and reported for the first time functional and phenotypic immunologic alterations in this rare inborn error of metabolism that would render the patient immunocompromised.
  • Evidence snippets:
  • Snippet 1 (score: 0.520) > The hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome is a rare autosomal recessive inborn error of the urea cycle caused by mutations in the SLC25A15 gene. Besides the well-known metabolic complications, patients often present intercurrent infections associated with acute hyperammonemia and metabolic decompensation. However, it is currently unknown whether intercurrent infections are associated with immunological alterations besides the known metabolic imbalances. Herein, we describe the case of a 3-years-old girl affected by the HHH syndrome caused by two novel SLC25A15 gene mutations associated with immune phenotypic and functional alterations. She was admitted to the hospital with an episode of recurrent otitis, somnolence, confusion, and lethargy. Laboratory tests revealed severe hyperammonemia, elevated serum levels of liver transaminases, hemostasis alterations, hyperglutaminemia and strikingly increased orotic aciduria. Noteworthy, serum protein electrophoresis showed a reduction in the gamma globulin fraction. Direct sequencing of the SLC25A15 gene revealed two heterozygous non-conservative substitutions in the exon 5: c.649G>A (p.Gly217Arg) and c.706A>G (p.Arg236Gly). In silico analysis indicated that both mutations significantly impair protein structure and function and are consistent with the patient clinical status confirming the diagnosis of HHH syndrome. In addition, the immune analysis revealed reduced levels of serum IgG and striking phenotypic and functional alterations in the T and B cell immune compartments. Our study has identified two non-previously described mutations in the SLC25A15 gene underlying the HHH syndrome. Moreover, we are reporting for the first time functional and phenotypic immunologic alterations in this rare inborn error of metabolism that would render the patient immunocompromised and might be related to the high frequency of intercurrent infections observed in patients bearing urea cycle disorders. Our results point out the importance of a comprehensive analysis to gain further insights into the underlying pathophysiology of the disease that would allow better patient care and quality of life

[3] The hyperornithinemia–hyperammonemia-homocitrullinuria syndrome

  • Authors: D. Martinelli, D. Diodato, Emanuela Ponzi, M. Monné, S. Boenzi et al.
  • Year: 2015
  • Venue: Orphanet Journal of Rare Diseases
  • URL: https://www.semanticscholar.org/paper/ed033868ee677da141e5c926bc7c93cac242ea06
  • DOI: 10.1186/s13023-015-0242-9
  • PMID: 25874378
  • PMCID: 4358699
  • Citations: 93
  • Influential citations: 5
  • Summary: The clinical phenotype of HHH syndrome is extremely variable and its severity does not correlate with the genotype or with recorded ammonium/ornithine plasma levels, suggesting the need for a better understanding of the still unsolved pathophysiology of the disease.
  • Evidence snippets:
  • Snippet 1 (score: 0.513) > Although the disease responds well to treatment with low risk of relapse of hyperammonemia [38], slowly progressive pyramidal signs characterize the chronic course, as also seen in argininemia [89]. However, the mechanism(s) of pyramidal dysfunction in HHH syndrome still remains to be elucidated. Creatine deficiency may contribute to the pathogenetic mechanism of the syndrome, as creatine is relevant for mitochondrial energy metabolism, regulation of glycolysis, proteins synthesis, membrane stabilization and neuromodulation [77,78,85]. This could be in line with the finding of abnormally shaped mitochondria at electron microscopy studies in skin fibroblasts, hepatocytes and muscle biopsy from HHH syndrome patients [11,23,82]. Furthermore, a mitochondrial dysfunction has been recently related to the effects of ornithine and homocitrulline in causing oxidative stress and disturbed mitochondrial homeostasis [79,80]. > A further mechanism that can be involved in the pathophysiology of HHH syndrome is related to polyamines metabolism. Shimizu and colleagues reported increased total and fractional (putrescine, cadaverine, spermine, spermidine) polyamines in one HHH syndrome patient [30]. Indeed, the clinical similarities between HHH syndrome and argininemia, which has been associated to an abnormal polyamine metabolism [91,92], may suggest a common pathogenetic mechanism causing pyramidal dysfunction. > Overall, the pathogenesis of HHH syndrome is complex and not completely understood. It is likely that different mechanisms, including the impact of low mitochondrial ornithine on UC flux, the presence of hyperammonemic crises and the disturbance of other pathways in major organs play a role in determining the heterogeneous clinical presentation of ORC1 deficiency. > In addition, as molecular studies failed to disclose a correlation between type of mutations or ornithine transport capacity and disease severity, an effect of genetic modifiers, such as ORC genes redundancy, seems to be likely, but further studies are certainly needed to clarify this point.
  • Snippet 2 (score: 0.471) > Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH, MIM #238970) syndrome is a rare genetic disorder of the urea cycle (UC) caused by mutations in the SLC25A15 or ORNT1 gene (MIM*603861), which encodes for the mitochondrial ornithine carrier ORC1 [1]. HHH syndrome represents a heterogeneous disease with high clinical variability, ranging from a mild form with learning difficulties and slight neurological involvement, to a more severe form with coma, lethargy, hepatic signs and seizures. Asides from the severe neonatal form, there is no evidence of a direct correlation between age of onset, which is variable, and disease severity [1]. As for other urea cycle disorders (UCDs), early diagnosis in infancy or childhood may improve the clinical outcome [1]. Acute treatment requires an emergency approach, whereas the long-term treatment consists of a lowprotein diet supplemented with citrulline or arginine; in some patients, sodium benzoate and/or sodium phenylbutyrate are used to maintain blood ammonia in a safe range [1]. In this paper, we aim to provide a comprehensive review of the genetic and molecular aspects of HHH syndrome, a descriptive picture of clinical features and therapeutic strategies along with a discussion on the still unsolved questions related to the disease pathomechanisms.
  • Snippet 3 (score: 0.457) > The hyperornithinemia–hyperammonemia-homocitrullinuria syndrome
  • Snippet 4 (score: 0.435) > BackgroundHyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome is a rare autosomal recessive disorder of the urea cycle. HHH has a panethnic distribution, with a major prevalence in Canada, Italy and Japan. Acute clinical signs include intermittent episodes of vomiting, confusion or coma and hepatitis-like attacks. Alternatively, patients show a chronic course with aversion for protein rich foods, developmental delay/intellectual disability, myoclonic seizures, ataxia and pyramidal dysfunction. HHH syndrome is caused by impaired ornithine transport across the inner mitochondrial membrane due to mutations in SLC25A15 gene, which encodes for the mitochondrial ornithine carrier ORC1. The diagnosis relies on clinical signs and the peculiar metabolic triad of hyperammonemia, hyperornithinemia, and urinary excretion of homocitrulline. HHH syndrome enters in the differential diagnosis with other inherited or acquired conditions presenting with hyperammonemia.MethodsA systematic review of publications reporting patients with HHH syndrome was performed.ResultsWe retrospectively evaluated the clinical, biochemical and genetic profile of 111 HHH syndrome patients, 109 reported in 61 published articles, and two unpublished cases. Lethargy and coma are frequent at disease onset, whereas pyramidal dysfunction and cognitive/behavioural abnormalities represent the most common clinical features in late-onset cases or during the disease course. Two common mutations, F188del and R179* account respectively for about 30% and 15% of patients with the HHH syndrome. Interestingly, the majority of mutations are located in residues that have side chains protruding into the internal pore of ORC1, suggesting their possible interference with substrate translocation. Acute and chronic management consists in the control of hyperammonemia with protein-restricted diet supplemented with citrulline/arginine and ammonia scavengers. Prognosis of HHH syndrome is variable, ranging from a severe course with disabling manifestations to milder variants compatible with an almost normal life.ConclusionsThis paper provides detailed information on the clinical, metabolic and genetic profiles of all HHH syndrome patients published to date. The clinical phenotype is extremely variable and its severity does not correlate with the genotype or with recorded

[4] Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome

  • Authors: Unknown authors
  • Year: 2020
  • Venue: Definitions
  • URL: https://www.semanticscholar.org/paper/c60059d910318f8e61dc2b4654fc9877c39fc2c6
  • DOI: 10.32388/ec0x7n
  • Summary: An autosomal recessive disorder caused by mutation(s) in the SLC25A15 gene, encoding mitochondrial ornithine transporter 1. The condition is characterized by failure to thrive, liver dysfunction, psychomotor retardation, encephalopathy and seizures.
  • Evidence snippets:
  • Snippet 1 (score: 0.505) > Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome

[5] Hyperornithinemia‐hyperammonemia‐homocitrullinuria syndrome in pregnancy: Considerations for management and review of the literature

  • Authors: Bernice Ho, J. MacKenzie, J. Walia, M. Geraghty, Graeme N. Smith et al.
  • Year: 2019
  • Venue: JIMD Reports
  • URL: https://www.semanticscholar.org/paper/8e5ac7ecb394e92fd984385c83e1002e663c9810
  • DOI: 10.1002/jmd2.12025
  • PMID: 31240152
  • PMCID: 6498866
  • Citations: 5
  • Summary: Recommendations for pregnancy management are made, including a detailed protocol for clinicians to use for disease management at delivery and in the post‐partum period, and a new concern of fetal intrauterine growth restriction is identified.
  • Evidence snippets:
  • Snippet 1 (score: 0.495) > Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome (MIM 238970) is a rare autosomal recessive, urea cycle disorder. 1 First described in 1969, 2 HHH syndrome is caused by mutations of the SLC5A15 gene, which codes for the mitochondrial ornithine carrier ORC1. 1 Classical presentation of the condition consists of a combination of clinical and biochemical signs of hyperammonemia, hyperornithinemia, and urine excretion of homocitrulline. 1 Clinical presentation includes irregular episodes of vomiting, confusion, and hepatitis-like attacks. 1 Patients can also demonstrate chronic clinical signs, including avoidance of protein-rich foods, psychological disorders, ataxia, seizures, and pyramidal dysfunction. 1 The treatment for HHH syndrome is similar to other urea cycle conditions and early diagnosis may improve clinical progression. Long-term management entails a low-protein diet based on ammonia levels and amino acid profiles, supplementation with citrulline or arginine, essential amino acids as required, and possibly ammonia lowering agents, such as sodium benzoate or sodium phenylbuterate. 3 In addition, additional calories to spare protein are often required. > HHH syndrome is a rare metabolic disorder with approximately 100 patients reported in the literature. 1 To our knowledge, there are less than three patients with successful pregnancies and deliveries found in the literature. [4][5][6] We summarize the current state of knowledge regarding HHH and pregnancy, and suggest a protocol for management during metabolic decompensation (Table 1).

[6] Clinical heterogeneity of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome in thirteen palestinian patients and report of a novel variant in the SLC25A15 gene

  • Authors: Imad Dweikat, R. Khalaf-Nazzal
  • Year: 2022
  • Venue: Frontiers in Genetics
  • URL: https://www.semanticscholar.org/paper/d74932b6a6a1553d383e10dc57f14fae430cd782
  • DOI: 10.3389/fgene.2022.1004598
  • PMID: 36506307
  • PMCID: 9730883
  • Citations: 5
  • Influential citations: 1
  • Summary: The results confirm the marked clinical heterogeneity of HHH including severe neonatal presentation, hepatic failure, and progressive pyramidal tract dysfunction in all age groups and report a novel pathogenic variant in the SLC25A15 gene, further expanding the molecular spectrum of the disease.
  • Evidence snippets:
  • Snippet 1 (score: 0.485) > Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) syndrome (Phenotype MIM number 238970) is a rare genetic disease of the urea cycle caused by disease-causing variants in the Solute Carrier Family 25, Member 15 gene; SLC25A15 (alias Ornithine Transporter, Mitochondrial, one; ORNT1, gene MIM number 603861) (Camacho et al., 1999;Tsujino et al., 2000;Salvi et al., 2001;Martinelli et al., 2015). Disease-causing variants in this gene result in impaired ornithine transport across the mitochondrial membrane; this interrupts the urea cycle and causes hyperammonemia. Impaired transport of ornithine causes its accumulation in the cytosol leading to hyperornithinemia (Oyanagi et al., 1983;Camacho et al., 1999). Inside the mitochondria, ornithine deficiency leads to the accumulation of carbamoylphosphate (Hommes et al., 1986;Inoue et al., 1988). The increased mitochondrial level of carbamoylphosphate results in either an excess production of orotic acid through the cytosolic pyrimidine biosynthetic pathway or the formation of homocitrulline from lysine by ornithine transcarbamylase (Panza et al., 2019). The combination of Hyperornithinemia, Hyperammonemia, and Homocitrullinuria is pathognomonic for HHH syndrome and is usually accompanied by the detection of increased levels of orotic acid in plasma or urine. However, initially, some patients may present with incomplete biochemical profiles such as normal plasma ornithine levels or minimal excretion of homocitrulline in urine (Shimizu et al., 1990;Martinelli et al., 2015). > HHH is characterized by marked phenotypic variability including age at onset, clinical presentation, and severity of symptoms.
  • Snippet 2 (score: 0.462) > Background: Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) syndrome, is a rare autosomal recessive disorder characterized by impaired ornithine transport across the inner mitochondrial membrane. HHH is caused by biallelic disease-causing variants in the SLC25A15 gene. The clinical presentation of HHH is highly variable ranging from severe neonatal encephalopathy and hepatic failure to a milder form with corresponding learning difficulties. Methods: In this study, data from thirteen patients with HHH syndrome, diagnosed between the age of 1 week–29 years at two tertiary care centers in Palestine, is presented. The clinical, biochemical, and molecular data are reviewed. Results: Analysis of the SLC25A15 gene sequence revealed a novel homozygous frameshift deletion in exon 5, NM_014252.4:c.552-555delTTTC; p (Phe185SerfsTer8) in nine patients. The remaining four patients had a recurrent homozygous frameshift variant; NM_014252.4:c.446delG, (p.Ser149ThrfsTer45). The major acute clinical presentation found was encephalopathy and liver dysfunction. Nervous system involvement was common, progressive, and presented with signs of upper motor neuron disease as well as variable degrees of cognitive impairment. One patient had an initial presentation in adulthood with acute encephalopathy that responded well to treatment. There was no clear genotype-phenotype correlation. Conclusion: Our results confirm the marked clinical heterogeneity of HHH including severe neonatal presentation, hepatic failure, and progressive pyramidal tract dysfunction in all age groups. The disease progression was variable, even in patients with the same genetic variant, and in patients with severe neonatal-onset hepatic encephalopathy. We report a novel pathogenic variant in the SLC25A15 gene, further expanding the molecular spectrum of the disease.

[7] Hyperornithinemia–Hyperammonemia–Homocitrullinuria Syndrome in Vietnamese Patients

  • Authors: Khanh Ngoc Nguyen, V. Tran, N. Nguyen, Thi Bich Ngoc Can, Thi Kim Giang Dang et al.
  • Year: 2024
  • Venue: Medicina
  • URL: https://www.semanticscholar.org/paper/f82156789e5dd35cf5b0ac96c15b838cccaced3f
  • DOI: 10.3390/medicina60111877
  • PMID: 39597062
  • PMCID: 11596723
  • Citations: 1
  • Summary: The results highlighted the clinical and biochemical heterogeneity of HHH syndrome and posed that HHH syndrome should be considered when individuals have hyperammonemia, elevated transaminase, and decreased prothrombin time.
  • Evidence snippets:
  • Snippet 1 (score: 0.481) > Those with later onset may display chronic neurocognitive deficits and/or unexplained seizures, spasticity, acute encephalopathy secondary to hyperammonemic crisis, or chronic liver dysfunction. > Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome can be diagnosed by mutations in the SLC25A15 gene and marked by elevated ammonia, homocitrulline, and ornithine levels [6]. HHH syndrome differs from other defects due to high urinary homocitrulline and ornithine [7]. Hyperornithinemia is present in almost all patients; however, a small proportion does not exhibit hyperammonemia and homocitrullinuria. Therefore, genetic testing for SLC25A15 variants accompanied by at least one of three metabolic traits, hyperornithinemia, hyperammonemia, and homocitrullinuria, is pivotal for a definite diagnosis of HHH syndrome [8]. Early diagnosis improves clinical outcomes [8]. Acute treatment of HHH syndrome is similar to other urea cycle disorders, whereas long-term treatment of HHH syndrome is similar to carbamoyl phosphate synthetase I and ornithine transcarbamylase deficiency [7]. Protein restriction, citrulline, arginine, supplementation of essential amino acids, and sodium benzoate/sodium phenylbutyrate are required. > The pathogenic variants in the SLC25A15 gene, an autosomal recessive inheritance pattern, cause hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome [2]. The SLC25A15 gene is located on chromosome 13q14.11 and comprises seven exons encoding for isoform 1 of the ornithine carrier ORC1 with a length of 301 amino acids [9]. The substrate binding of the ORC1 includes Glu77, Arg179, and Glu180 residues, and the Asn74 and Asn78 are situated in the substrate binding pocket [10].

[8] Hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome: a treatable genetic liver disease warranting urgent diagnosis.

  • Authors: Hencher Han-Chih Lee, K. Poon, C. Lai, K. Au, T. Siu et al.
  • Year: 2014
  • Venue: Hong Kong medical journal = Xianggang yi xue za zhi
  • URL: https://www.semanticscholar.org/paper/66906e104ea0ceee49e6bad83c0ccda03c30bdeb
  • DOI: 10.12809/hkmj133826
  • PMID: 24473688
  • Citations: 15
  • Summary: Optimal management of these two patients relied on the concerted efforts of a multidisciplinary team and illustrates the importance of an expanded newborn screening service for early detection and treatment of inherited metabolic diseases.
  • Evidence snippets:
  • Snippet 1 (score: 0.471) > Hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome: a treatable genetic liver disease warranting urgent diagnosis.

[9] Hereditary Spastic Paraplegia Is a Common Phenotypic Finding in ARG1 Deficiency, P5CS Deficiency and HHH Syndrome: Three Inborn Errors of Metabolism Caused by Alteration of an Interconnected Pathway of Glutamate and Urea Cycle Metabolism

  • Authors: Emanuele Panza, D. Martinelli, P. Magini, C. Dionisi Vici, M. Seri
  • Year: 2019
  • Venue: Frontiers in Neurology
  • URL: https://www.semanticscholar.org/paper/2743986e24a75ea2b24c004e412709715c1d6e2a
  • DOI: 10.3389/fneur.2019.00131
  • PMID: 30853934
  • PMCID: 6395431
  • Citations: 24
  • Influential citations: 2
  • Summary: Comment on these forms, on the common features among them and on the hypotheses for possible shared pathogenetic mechanisms causing the HSP phenotype are commented on.
  • Evidence snippets:
  • Snippet 1 (score: 0.457) > The association of hyperornithinaemia, hyperammonaemia, and homocitrullinuria is pathognomonic for HHH syndrome (MIM#238970), an autosomal recessive disease caused by biallelic mutations in SLC25A15 gene (alias ORNT1, MIM#603861). This gene maps on 13q14.11, and it encodes for the mitochondrial ornithine/citrulline antiporter ORC1. Mutations in this gene result in a defect of ornithine transport through the mitochondrial membrane (Figure 1), causing a functional deficiency of the urea cycle. This mechanism results in the increase of ornithine levels in cytosol (and in plasma), while causing ornithine deficiency inside mitochondria, affecting the urea cycle. The latter situation leads to the accumulation of carbamoylphosphate, which is shifted to the formation of orotic acid by an alternative pathway, and induces the formation of homocitrulline from lysine by ornithine transcarbamylase. > HHH can occur at any age (15)(16)(17). The clinical presentation of HHH syndrome covers a broad spectrum of symptoms, including protein intolerance, vomiting, seizures, confusion, and developmental delay. The most severe forms have been reported with neonatal onset of lethargy, hypotonia, and seizures developing into coma and even death (18). There are also slowly/chronic progressive forms, characterized by the patients aversion to food rich in proteins, variable intellectual disabilities and/or cognitive regression, and signs of motor deficit (18). > Most patients develop neurological dysfunction mainly characterized by pyramidal tract signs with spastic gait, associated with cerebellar symptoms (Table 1).
  • Snippet 2 (score: 0.448) > Hereditary Spastic Paraplegias (HSPs) are a clinically and genetically heterogeneous group of neurodegenerative disorders characterized by a progressive rigidity and weakness of the lower limbs, caused by pyramidal tract lesions. As of today, 80 different forms of HSP have been mapped, 64 genes have been cloned, and new forms are constantly being described. HSPs represent an intensively studied field, and the functional understanding of the biochemical and molecular pathogenetic pathways are starting to be elucidated. Recently, dominant and recessive mutations in the ALDH18A1 gene resulting in the deficiency of the encoded enzyme (delta-1-pyrroline-5-carboxylate synthase, P5CS) have been pathogenetically linked to HSP. P5CS is a critical enzyme in the conversion of glutamate to pyrroline-5-carboxylate, an intermediate that enters in the proline biosynthesis and that is connected with the urea cycle. Interestingly, two urea cycle disorders, Argininemia and Hyperornithinemia-Hyperammonemia-Homocitrullinuria syndrome, are clinically characterized by highly penetrant spastic paraplegia. These three diseases represent a peculiar group of HSPs caused by Inborn Errors of Metabolism. Here we comment on these forms, on the common features among them and on the hypotheses for possible shared pathogenetic mechanisms causing the HSP phenotype.
  • Snippet 3 (score: 0.448) > Hereditary Spastic Paraplegias (HSPs) are a clinically and genetically heterogeneous group of neurodegenerative disorders characterized by a progressive rigidity and weakness of the lower limbs, caused by pyramidal tract lesions. As of today, 80 different forms of HSP have been mapped, 64 genes have been cloned, and new forms are constantly being described. HSPs represent an intensively studied field, and the functional understanding of the biochemical and molecular pathogenetic pathways are starting to be elucidated. Recently, dominant and recessive mutations in the ALDH18A1 gene resulting in the deficiency of the encoded enzyme (delta-1-pyrroline-5-carboxylate synthase, P5CS) have been pathogenetically linked to HSP. P5CS is a critical enzyme in the conversion of glutamate to pyrroline-5-carboxylate, an intermediate that enters in the proline biosynthesis and that is connected with the urea cycle. Interestingly, two urea cycle disorders, Argininemia and Hyperornithinemia-Hyperammonemia-Homocitrullinuria syndrome, are clinically characterized by highly penetrant spastic paraplegia. These three diseases represent a peculiar group of HSPs caused by Inborn Errors of Metabolism. Here we comment on these forms, on the common features among them and on the hypotheses for possible shared pathogenetic mechanisms causing the HSP phenotype.

[10] Late onset hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome, presenting as recurrent metabolic encephalopathy, A case report

  • Authors: Fajr M A Sarhan, Afnan W. M. Jobran, Ali Fayyad, Zaid Ghanim, Imad Dweikat et al.
  • Year: 2022
  • Venue: Annals of Medicine and Surgery
  • URL: https://www.semanticscholar.org/paper/2f02f0c9134c07db7e3199404d2988c7f42ea035
  • DOI: 10.1016/j.amsu.2022.104842
  • PMID: 36582900
  • PMCID: 9793129
  • Summary: High suspicion for genetic causes of metabolic encephalopathy should be maintained even for older patients without prior diagnosis in childhood/adolescence, and treatment focuses on reduction of the ammonia levels using sodium benzoat, citrulline or arginine, and low protein diet.
  • Evidence snippets:
  • Snippet 1 (score: 0.444) > Late onset hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome, presenting as recurrent metabolic encephalopathy, A case report

[11] Amino Acid Metabolism in Liver Mitochondria: From Homeostasis to Disease

  • Authors: Ranya Erdal, Kıvanç Birsoy, G. Unlu
  • Year: 2025
  • Venue: Metabolites
  • URL: https://www.semanticscholar.org/paper/2c1c09359e82a1bec3601ec57b7b48eaca82c5c0
  • DOI: 10.3390/metabo15070446
  • PMID: 40710547
  • PMCID: 12300550
  • Citations: 4
  • Summary: It is discussed how emerging genetic and metabolic interventions—including dietary modulation, cofactor replacement, and gene therapy—are reshaping treatment of liver-based metabolic disorders and reveals actionable vulnerabilities in metabolic disease and cancer.
  • Evidence snippets:
  • Snippet 1 (score: 0.440) > 4.1. Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome (SLC25A15 Deficiency) > Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome is a rare autosomal recessive urea cycle disorder resulting from a deficiency in the SLC25A15 gene, which encodes ornithine carrier 1 (ORC1). ORC1 plays a critical role in facilitating the transport of ornithine into the mitochondria and citrulline out of the mitochondria, thus enabling proper urea cycle function (Figure 1). Dysfunction in ORC1 results in the accumulation of ornithine in the cytosol, leading to hyperornithinemia. The consequent reduction of mitochondrial ornithine levels diminishes the activity of OTC, resulting in elevated carbamoyl phosphate levels and subsequent hyperammonemia. Increased carbamoyl phosphate levels, due to decreased OTC activity, further account for the increased urinary excretion of orotic acid as carbamoyl phosphate enters the pyrimidine synthesis pathway. Clinical manifestations of HHH syndrome are akin to those observed in other proximal urea cycle disorders (Table 1). Affected individuals experience symptoms of hyperammonemia, including lethargy, vomiting, failure to thrive, seizures, and, in severe cases, coma [36].

[12] Severe Neurological Sequelae and Radiological Findings in a Lost-to-Follow-Up Case of Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome

  • Authors: A. Mohamed, Ahaan Gupta, Reem Zakzouk
  • Year: 2025
  • Venue: Cureus
  • URL: https://www.semanticscholar.org/paper/c3c1d501580ab638319ec42bf3b1ee932b897edb
  • DOI: 10.7759/cureus.93690
  • PMID: 41189871
  • PMCID: 12580580
  • Summary: Investigations demonstrated radiological evidence of neurological damage, including corpus callosal atrophy, alongside biochemical and ultrasonographic features of hepatic dysfunction, alongside biochemical and ultrasonographic features of hepatic dysfunction in a patient who was treated for hyperammonemic crisis at birth and subsequently diagnosed with HHH syndrome.
  • Evidence snippets:
  • Snippet 1 (score: 0.435) > Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome is a rare autosomal recessive urea cycle disorder caused by defective hepatic ornithine transport, leading to hyperammonemia and progressive neurological complications. We report the case of a patient who was treated for hyperammonemic crisis at birth and subsequently diagnosed with HHH syndrome. Management, including ammonia-lowering therapy and a low-protein diet, was initiated; however, due to significant socioeconomic barriers, he was lost to follow-up from the age of two. He re-presented at the age of 12 in a severely debilitated state with global developmental delay and refractory epilepsy. Investigations demonstrated radiological evidence of neurological damage, including corpus callosal atrophy, alongside biochemical and ultrasonographic features of hepatic dysfunction. This case highlights the critical importance of sustained treatment, multidisciplinary follow-up, and adequate social support in preventing irreversible complications of HHH syndrome.

[13] Mitochondrial Dysfunction in Diabetes: Shedding Light on a Widespread Oversight

  • Authors: F. Iheagwam, A. J. Joseph, E. D. Adedoyin, Olawumi Toyin Iheagwam, Samuel Akpoyowvare Ejoh
  • Year: 2025
  • Venue: Pathophysiology
  • URL: https://www.semanticscholar.org/paper/dbf8042761c1a5fc50f8cd894cc498505abac7cb
  • DOI: 10.3390/pathophysiology32010009
  • PMID: 39982365
  • PMCID: 12077258
  • Citations: 30
  • Summary: This review aims to elucidate the complex link between mitochondrial dysfunction and diabetes, covering the spectrum of diabetes types, the role of mitochondria in insulin resistance, highlighting pathophysiological mechanisms, mitochondrial DNA damage, and altered mitochondrial biogenesis and dynamics.
  • Evidence snippets:
  • Snippet 1 (score: 0.432) > The landscape of DM research is continuously evolving, with emerging technologies and approaches offering new insights into the pathophysiology of the disease and potential therapeutic targets. Advancements in omics technologies, encompassing genomes, transcriptomics, proteomics, and metabolomics, have transformed the molecular mechanisms underlying DM [134]. High-throughput sequencing techniques enable comprehensive analysis of genetic variants, gene expression profiles, protein abundance, and metabolite levels associated with DM and its complications [135]. Single-cell omics approaches provide unprecedented resolution and granularity, allowing researchers to dissect cellular heterogeneity and identify novel cell types, subpopulations, and signalling pathways involved in DM pathogenesis. Integrating multi-omics data sets offers a systems-level perspective of DM, unravelling complex networks of molecular interactions and regulatory circuits underlying disease progression [136]. > In addition to omics technologies, advances in imaging modalities, such as MRI, PET, and optical imaging, enable non-invasive visualisation and quantification of metabolic, functional, and structural changes. Molecular imaging probes targeting specific biomarkers and metabolic pathways provide valuable insights into disease mechanisms and treatment responses in preclinical and clinical settings [85]. Despite significant progress in DM research, numerous unanswered questions and knowledge gaps persist, hindering the ability to develop effective prevention and treatment strategies. Key areas requiring further investigation include the role of epigenetics, environmental factors, and the microbiome in DM susceptibility and progression. Moreover, the interaction between environmental cues and genetic predisposition remains incompletely understood, highlighting the need for comprehensive multi-omics studies and large-scale epidemiological analyses to identify gene-environment interactions and modifiable risk factors for DM [137]. Furthermore, the heterogeneity of DM phenotypes and clinical outcomes poses a challenge for personalised medicine approaches, necessitating robust biomarkers and predictive models to stratify patients based on disease subtypes, prognosis, and treatment response [138].

Notes

  • This provider combines search_papers_by_relevance with snippet_search.
  • No synthesis or second-stage model call is performed.